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1 Abstract/Zusammenfassung 
1 Abstract/Zusammenfassung 
In recent years neurodegeneration in MS has become a focus of research since it is 
thought to be the main determinant of irreversible neurological disabilities in patients. 
The relationship between inflammation and neurodegeneration is not fully 
understood. An animal model of MS, myelin oligodendrocyte glycoprotein (MOG) -
induced experimental autoimmune encephalomyelitis (EAE) was used to examine 
the temporal relationship between early neurodegeneration, optic neuritis and 
changes in the retina and optic nerve. Fluorogold-labeling of retinal ganglion cells 
(RGCs), histopathological staining and immunohistochemistry with antibodies 
identifying T-cells and microglia/macrophages in the optic nerve confirmed previous 
results, that degeneration of RGCs can be observed prior to the onset of clinical 
symptoms and optic neuritis, which is characterized by demyelination, axonal loss 
and infiltration with inflammatory cells. There is, however, significant activation of 
resident microglia in the optic nerve and retina prior to onset of optic neuritis, 
correlating with the onset of RGC degeneration. This indicates that activated 
microglia could be involved in early death of RGCs and might cause subtle axonal 
changes prior to onset of clinical symptoms and optic neuritis.  
The mechanisms of axonal damage and RGC degeneration are not well understood 
but are likely to involve calcium influx and subsequent activation of the calcium-
activated protease calpain. Experiments using manganese-enhanced MRI were 
performed, showing increased calcium influx in the optic nerve and retina during the 
induction phase, prior to onset of optic neuritis and calcium influx in the retina 
correlated with onset of RGC degeneration. Blocking experiments showed 
involvement of NMDA receptors in manganese enhancement in the retina during the 
induction phase of the disease. 
Calpain activity was examined by performing western blots with an antibody specific 
to one of the calpain-mediated spectrin breakdown products (145 kDa, BDPN). 
Increased amount of BPDN in the optic nerve was observed during the induction 
phase, correlating with calcium influx and in the retina it correlated with onset of 
calcium influx and onset of RGC degeneration. Treatment of MOG-immunised 
animals with the calpain inhibitor calpeptin increased the number of surviving RGCs 
both during the induction phase and after onset of optic neuritis and also decreased 
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demyelination, infiltration with inflammatory cells and axonal disturbances (indicated 
by APP accumulation) in the optic nerve after onset of clinical symptoms.  
Taken together these data indicate that microglial activation might be involved in 
early degeneration of RGCs and that calcium influx and calpain activation correlates 
with the onset of RGC degeneration in the retina. Inhibition of calpain activity with 
calpeptin suggests that calpain activation plays a role in infiltration with inflammatory 
cells and in degeneration of RGCs since both have been shown to be reduced with 
calpeptin treatment. 
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In den letzten Jahren ist die Neurodegeneration bei Multipler Sklerose in den Fokus 
der Forschung gerückt, da man davon ausgeht, dass sie die hauptsächliche Ursache 
für irreversible neurologische Störungen bei Patienten ist. Der Zusammenhang 
zwischen Entzündung und Neurodegeneration ist nicht vollständig untersucht. Im 
Folgenden wurde ein Tiermodell der Multiplen Sklerose, MOG-induzierte 
Experimentelle Autoimmune Enzephalomyelitis (EAE), genutzt um den zeitlichen 
Zusammenhang zwischen früher Neurodegeneration, Optikusneuritis und 
Veränderungen in der Retina und im Sehnerv zu untersuchen. 
Das markieren von retinalen Ganglienzellen (RGC) mit Fluorogold, 
histopathologische und immunohistochemische Untersuchungen zur Identifizierung 
von T-Zellen und Mikroglia/Makrophagen im Sehnerv bestätigte frühere Ergebnisse, 
dass die Degeneration von retinalen Ganglienzellen bereits vor Eintreten der 
klinischen Symptome und vor Beginn der Optikusneuritis welche durch 
Demyelinisierung, Axonverlust und Infiltration mit inflammatorischen Zellen 
gekennzeichnet ist, zu beobachten ist. 
Es zeigte sich schon vor Beginn der Optikusneuritis eine signifikante Aktivierung von 
Mikroglia im optischen Nerv und der Retina, welche mit dem Beginn der 
Degeneration der retinalen Ganglienzellen korrelierte. Dies deutet darauf hin, dass 
aktivierte Mikroglia in der frühen Degeneration der retinalen Ganglienzellen eine 
Rolle spielen könnten und möglicherweise auch subtile axonale Veränderungen 
verursachen. 
Die Mechanismen die zur Degeneration von retinalen Ganglienzellen und axonalen 
Schäden führen sind noch nicht vollständig untersucht aber es ist anzunehmen, dass 
Calciumeinstrom und die nachfolgende Aktivierung der calcium-abhängigen Protease 
Calpain eine Rolle spielen. MRT Aufnahmen mit manganhaltigem Kontrastmittel 
deuten auf einen erhöhten Calciumeinstrom in der Retina und im Sehnerv hin der 
bereits vor Beginn der Optikusneuritis einsetzte. Der Calciumeinstrom in der Retina 
korrelierte dabei zeitlich mit dem Beginn der Degeneration der retinalen 
Ganglienzellen und Experimente mit einem NMDA Rezeptor Blocker deuten darauf 
hin, dass diese eine Rolle bei der Kontrastverstärkung in der Retina spielen könnten.  
Um die Calpain Aktivität zu bestimmen wurden Western Blots mit einem Antikörper 
durchgeführt der spezifisch ist für eines der Spaltprodukte von Spectrin, welches nur 
entsteht wenn Spectrin durch Calpain gespalten wird. 
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Eine erhöhte Konzentration des Spaltprodukts konnte im Sehnerv vor Beginn der 
Optikusneuritis festgestellt werden und korrelierte mit der beobachteten 
Kontrastverstärkung nach Manganinjektion. In der Retina war ebenfalls eine 
Erhöhung der Konzentration des Spaltprodukts zu finden, welche zeitlich mit der 
Kontrastverstärkung und dem Einsetzen der Degeneration von retinalen 
Ganglienzellen korrelierte. 
Die Behandlung der MOG-immunisierten Tiere mit dem Calpain-Inhibitor Calpeptin 
führte zu einer erhöhten Überlebensrate der retinalen Ganglienzellen vor Beginn der 
Optikusneuritis und auch im späteren Verlauf. Bei behandelten Tieren mit 
Optikusneuritis zeigte sich im Vergleich zu unbehandelten Tieren eine Reduktion der 
Demyelinisierung, weniger Infiltration mit inflammatorischen Zellen und eine 
reduzierte Störung des axonalen Transports (erkennbar durch reduzierte 
Akkumulation von APP positiven Axonen). 
Zusammenfassend deuten diese Daten darauf hin, dass Aktivierung von Mikroglia 
eine Rolle in der frühen Degeneration von retinalen Ganglienzellen spielen könnte 
und das Calciumeinstrom und Aktivierung der Protease Calpain in der Retina mit der 
Degeneration von retinalen Ganglienzellen korrelierten. Die Ergebnisse der 
Behandlungsstudie mit Calpeptin deuten darauf hin, dass Calpain Aktivität die 
Infiltration mit inflammatorischen Zellen beeinflusst und eine Rolle bei der 
Degeneration von retinalen Ganglienzellen spielt, da Beides in behandelten Tieren 
reduziert ist. 
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2 Introduction 
2.1 Multiple sclerosis 
Multiple sclerosis (MS) is an inflammatory, demyelinating autoimmune disease of the 
central nervous system (CNS). The age of onset is usually between twenty and forty 
years and it is the most common non-traumatic cause for neurological disability in 
young adults. MS is a complex genetic disease, meaning that genome aleic 
variations, postgenomic modification and environmental factors play a role in 
developing MS (Oksenberg and Hauser, 2008).  
2.1.1 Genetics of Multiple Sclerosis 
The genetic component of MS is amongst other things suggested by a higher 
incidence in some ethnic groups. People from northern European origin are at a 
higher risk than people from Africa and Asia. Environmental factors cannot explain 
these differences because resistant ethnic groups that reside in high-risk areas still 
show lower incidence for MS. For example Japanese living in North America have a 
lower incidence than the people of European descent in the same area (Detels et al., 
1977). The familial aggregation of MS also points to the role of a genetic component 
and it cannot be explained by a shared environment since adopted family members 
have the same susceptibility as the general population (Ebers et al., 1995). The risk 
of developing MS is approximately 0.1 % (Sadovnick and Ebers, 1993) in the general 
population but rises to 1-3 % if mother, father or a sibling is affected. The risk is even 
higher when a twin is affected. The concordance in monozygotic twins is much higher 
(20-40%) than in dizygotic twins (2-5 %) (Sadovnick et al., 1993), thus providing 
additional evidence for a genetic etiology of MS. On the other hand the discordance 
in monozygotic twins (after all only 20 – 40 % of the twins develop MS as well) also 
points to the role environmental factors play in disease development.  
The Major histocompatibility complex (MHC) is thought to play a major role in genetic 
susceptibility and disease course. The MHC is a region on chromosome 6 that can 
be found in most vertebrates and whose genes play an important role in the immune 
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system. The best known genes in this region encode for antigen presenting proteins. 
In humans the genes in this subset are called human leukocyte antigen (HLA) genes. 
The encoded proteins are expressed on the cell surface and present antigens to 
T-cells. The HLA genes are divided into two classes: HLA-I and HLA-II. The major 
genes of the HLA-I class are HLA-A, B and C, they encode for proteins which are all 
part of different surface receptors which present peptides from inside the cell to T-
cells. These surface receptors can be found on all cells. The proteins encoded by the 
genes of the HLA-II class can be found only on the surface of a few cell types, 
including macrophages, dendritic cells and B-cells which all belong to the 
professional antigen-presenting cells (APCs). The genes in this class are: HLA-
DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1 HLA-DRA and HLA-DRB. For each gene 
of both the HLA-I and II class numerous alleles and thus protein variations are 
known. 2,496 alleles are known for HLA-I and for HLA-II 1032 alleles are known 
(IMGT/HLA Database, 2009). A strong association with the HLA-DRB1 locus and the 
DR2 haplotype (DRB1*1501, DQB1*0602) have been confirmed in a study of 
multicase MS families in the USA (Barcellos et al., 2002). Other genes outside the 
HLA region have also been associated with MS, for example certain alleles of the 
interleukin-2 receptor α gene (IL2RA) and the interleukin-7 receptor α gene (IL7RA) 
(The International Multiple Sclerosis Genetics Consortium, 2007). 
 
2.1.2 Infectious agents in Multiple Sclerosis 
Apart from an inherited suceptibility for MS, environmental factors also play a role in 
developing MS. People of northern European origin who live outside of 
Europe/America have a much lower prevalence than those with a similar genetic 
background who live in high risk areas (Compston and Coles, 2002). It is known that  
viral infections can cause neurological diseases. In Subacute Sclerosing 
Panencephalitis (SSPE), a chronic inflammatory disease of white and gray matter, 
measles virus can be found in brain samples from patients (Payne et al., 1969). 
Progressive Multifocal Leukoencephalopathy (PML), a demyelinating disease, is 
caused by an infection with the JC virus, which can be found in oligodendrocytes of 
patients (Padgett et al., 1971). Evidence for an infectious nature of MS is the high 
concentration of IgG in the brain and cerebrospinal fluid (CSF) of more than 90 % of 
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MS patients. This IgG manifests as oligoclonal IgG bands (OGBs) and can be found 
in many other CNS diseases, for example SSPE and PML (Vandvik et al., 1976; 
Weber et al., 1997). The IgG in these diseases is directed against the virus which 
causes the disease but so far the antigenic target of the OGBs in MS remains 
elusive. The bacterium Chlamydophila pneumonia and the herpesviruses human 
herpesvirus 6 and Epstein-Barr virus (EBV) have been implicated to have a role in 
MS. For the first two no significant association was found (Tsai and Gilden, 2001; 
Liedtke et al., 1995; Mirandola et al., 1999) and while seroepidemiology studies show 
association between MS and EBV infection this might be due to a predisposition for 
both MS and certain viral infections (Niller et al., 2008) and thus does not prove a 
causative role for this virus. Further studies on the the specifity of the OGBs could 
help to identify the causative antigen. 
 
2.1.3 Different forms of Multiple Sclerosis 
MS can be separated into two groups: relapsing-remitting and chronic-progressive. 
Relapsing-remitting multiple sclerosis (RRMS) is the most common form of disease 
at onset, approximately 85 % of patients first present with this form and overall this 
subtype accounts for 55 % of MS cases (Committee on Multiple Sclerosis, 2001). In 
RRMS the reoccurrence of symptoms which last at least 24 hours, is followed by a 
period of remission in which the symptoms improve (Figure 2.1 A1) or disappear 
(Figure 2.1 A2). These remissions usually last between 4 and 8 weeks, and two 
attacks must be separated by at least 30 days before the time in between is 
considered as remission. In the beginning, the relapses are often followed by a 
complete recovery, however later on in the disease some deficits persist and 
eventually develop into the secondary progressive form of the disease (see SPMS) 
(Committee on Multiple Sclerosis, 2001).  
The chronic-progressive form can be separated into 3 different subtypes: Secondary-
Progressive MS (SPMS) occurs often following an initial course of RRMS which then 
turns into a progressive form with or without relapses (Figure 2.1 B1 and B2) Natural 
history studies of untreated RRMS indicate that 10 years after the onset of RRMS 50 
% of the patients would develop SPMS and after 25 years 90 % would develop 
SPMS. It is also the most common form of chronic-progressive MS and accounts for 
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30 % of MS cases (Committee on Multiple Sclerosis, 2001). The Primary-Progressive 
(PPMS) and Progressive-Relapsing (PRMS) forms of the disease are usually 
associated with a later onset (45 years or older), 15 % of patients presenting first with 
one of these two chronic-progressive forms. PPMS progresses continuously without 
flare-ups of symptoms (Figure 2.1 C1), sometimes with plateaus and temporary 
minor improvements (Figure 2.1, C2). PRMS is the least common form of MS, only 5 
% of patients first present with this form. PRMS is also progressive from the start but 
shows flare-up of symptoms. Between the attacks the disease progresses further. 
After an attack the level of disability can return to its former state (Figure 2.1 D1) or 
some disability from the attack can remain (Figure 2.1 D2). 
The neurological deficits in RRMS and SPMS are believed to have a different origin. 
In RRMS the reversible disability is caused by inflammation, oedema and 
demyelination and resolving of inflammation, reorganisation of sodium channels 
along the axon and ultimately remyelination are thought to contribute to clinical 
recovery after relapses (Brück, 2005). Anti-inflammatory therapies work well in 
RRMS emphasizing the role of inflammation at this point (Trapp and Nave, 2008). 
Once patients have developed SPMS the results of anti-inflammatory therapies are 
unsatisfactory. At this stage axonal loss causes ongoing, irreversible disability. 
Axonal loss occurs early in the disease but is clinically silent because the CNS can 
compensate the loss of neurons (Trapp et al., 1999). It is estimated that in other 
neurodegenerative diseases such as Parkinson´s disease and Amyotrophic Lateral 
Sclerosis, 50 – 80 % of target neurons need to be lost before compensatory 
mechanisms are no longer able to prevent neurological disability (Bradley, 1987; 
Lloyd, 1977). A comparison between patients with PPMS and RRMS leads to 
interesting new concepts regarding the course of the disease. Relapses in RRMS 
have very little effect on accumulation of permanent disability later in the disease. 
Patients with PPMS have few or no relapses and the age of onset is about 10 years 
later than in patients with RRMS but they still reach disability milestones around the 
same age (Confavreux and Vukusic, 2006 ; Trapp and Nave, 2008). This data 
indicates that neurodegeneration might start in both patient groups around the same 
time but patients with RRMS are diagnosed earlier because of clinical symptoms 
caused by inflammatory episodes at a time when the loss of axons is still in range of 
compensatory mechanisms and thus clinically silent (Fig. 1.2.) (Trapp et al., 1999). 
This emphazises the important role of neurodegeneration and also underlines the 
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unique opportunity of early intervention with neuroprotective therapies when only 
minimal axonal loss has taken place and there is chance to reduce ongoing axonal 
loss, irreversible disease progression and conversion from RRMS to SPMS. 
 
Figure 2.1 The four different forms of multiple sclerosis. Adapted from Lublin and Reingold, 
1996 
MS can be divided into two groups: relapsing-remitting and chronic progressive. Figure A shows 
Relapsing-remitting MS (RRMS), Figure B, C and D show the three forms of chronic progressive MS. 
RRMS is the most common form of MS and in time patients with RRMS often develop a Secondary-
Progressive MS (SPMS). Primary Progressive MS (PPMS) and Progressive-Relapsing MS are more 
uncommon with only 15 % of patients first present with these forms. 
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Figure 2.2 Transition from the clinical silent stage to chronic disability in MS Adapted from 
Trapp et al, 1999 
There is a clinically silent phase in all neurodegenerative diseases, in this phase the CNS can still 
compensate for neuronal loss. However because MS has both a neurodegenerative and an 
inflammatory component, symptoms occur very early in the disease course and the illness can be 
identified before axonal loss leads to irreversible disability.  
 
2.2 Disease pathology 
Inflammation and the formation of new white matter lesions are the hallmarks of 
acute MS and RRMS in particular. In the progressive phase new inflammatory 
lesions are rare and diffuse atrophy of grey and white matter takes place, as a 
consequence of which anti-inflammatory therapies are less efficient in the 
progressive phase of the disease (Coles et al., 2006). Inflammation is caused by 
autoreactive T-cells which cross the blood-brain barrier (BBB). Harmful autoreactive 
T-cells are mostly destroyed in the thymus during maturation but some of them 
escape and can be found in the periphery of healthy individuals as well as MS 
patients (Danke et al., 2004). These autoreactive T-cells are suppressed by 
regulatory T-cells (Treg) in healthy individuals. The function of the 
CD4+CD25highCD127low Tregs is not compromised in MS patients but the 
hyperproliferation of CD4+CD25highCD127high Tregs might interfere with their ability to 
suppress autoreactive T-cells and thus leading to higher numbers of active 
autoreactive T-cells (Michel et al., 2008). Autoeactive CD4+ T-cells produce cytokines 
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which activate adhesion molecules on the endothelium of the BBB (ICAM-1 and 
VCAM-1) and express receptors (LFA-1 and VLA-4) which allow them to adhere to 
and transmigrate through the endothelium (Baron et al., 1993; Engelhard and 
Ransohoff, 2005; Sospedra and Martin, 2008). The sites of injury in the CNS are 
called plaques. In active plaques, the BBB is disturbed which is accompanied by a 
leakage of serum proteins (Kirk et al., 2003). The plaques are infiltrated with 
inflammatory cells and show increased levels of chemokines expressed by 
astrocytes, T-cells and microglia/macrophages (Simpson et al, 1998; Sørensen et al., 
1999; Balashov et al, 1999; Sindern et al., 2001). Pro-inflammatory cytokines 
expressed by T-cells and microglia/macrophages (Cua et al., 2003; Sospedra and 
Martin, 2008) contribute to further activation of resident cells like astrocytes and 
microglia, BBB opening and axonal injury (Compston and Coles, 2002), while the 
chemokines are responsible for the recruitment of B-cells, T-cells and monocytes 
from the peripheral blood. Myelin breakdown starts in the plaque and macrophages 
contain early myelin breakdown products pointing to their role in myelin clearance 
(Patrikios et al., 2006). In the chronic active plaque a thin rim of active myelin 
breakdown is present but the core of the lesion resembles a chronic inactive lesion 
(Hickey, 1999). Infiltrating cells are still present and there is evidence that the BBB is 
still disturbed (Kirk et al., 2003). Astrocytes in the demyelinated area undergo 
morphological changes and increase expression of glial fibrillary acidic protein 
(GFAP) (Hickey, 1999). The socalled reactive astrocytes (defined by their increased 
GFAP expression) synthesise more cytoskeletal proteins and extend pseudopodia. 
Ultimately they form a dense web of plasma membrane extensions and thus become 
a major contributor to the glial scar (Stichel and Müller, 1998).  
Chronic inactive plaques are in general quiescent glial scars formed by reactive 
astrocytes. The numbers of infiltrating inflammatory cells is greatly diminished. 
Shadow plaques have a thin layer of myelin and show faint staining with Luxol Fast 
Blue. This is the result of partial or complete remyelination. The plaques can be 
distinguished from active plaques by a few characteristics: shadow plaques show a 
reduction of axonal density, low number of inflammatory infiltrates and no 
macrophages with early myelin degradation products (Patrikios et al,. 2006) 
The mechanisms of demyelination can be divided into four patterns (Lucchinetti et 
al., 2000): In pattern I and II, active demyelination is linked to T-cell and macrophage-
dominated inflammation. In pattern I, the destructive process is most likely induced 
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by toxic products from macrophages. Deposition of immunoglobulins (Ig) and 
complement antigen C9neo can only be found in pattern II and are the major features 
that distinguish these two patterns. The deposition at sites of active demyelination 
suggests an important role for antibodies in this pattern. These two patterns of 
demyelination show high numbers of oligodendrocytes in the center of inactive 
lesions and a high incidence of remyelinated shadow plaques. 
Patterns III and IV show signs of oligodendrocyte dystrophy. In pattern III, the 
processes of oligodendrocytes are more affected than the cell body. This is 
consistent with a dying back oligodendropathy which was first described in 
oligodendrocytes after Cuprizone administration (Ludwin and Johnson, 1981), and 
can also be found in MAG-deficient mice (Lassman et al., 1997) which fits to the fact 
that in this pattern the expression of the myelin-associated-glycoprotein (MAG) is 
reduced. Dying-back neuropathies are characerised by the inability of the cell to 
maintain the metabolic processes neccesary to support the distal part of the axon. 
Therefore the axon starts to degenerate from the periphery and the cell body might 
remain intact for some time. In pattern IV, primary oligodendrocyte death in the 
periplaque white matter leads to secondary demyelination. The reason for the 
degeneration of oligodendyrocytes is unclear; it might be due to a genetic defect 
which renders the cells vulnerable to toxic mediators. In both patterns the inactive 
center shows a nearly complete loss of oligodendrocytes and remyelinated shadow 
plaques are absent in these patterns. Remyelinated shadow plaques usually present 
with less pronounced axonal injury, failure of remyelination is therefore likely to 
contribute to axonal injury. Several mechanisms for this failure have been discussed. 
After remyelination the number of oligodendrocytes in the area is higher than before 
(Prayoonwiwat and Rodriguez, 1993), which implies the generation of new 
oligodendrocytes. Post-mitotic oligodendrocytes are not able to form a new myelin 
sheath around the axon when transplanted into demyelinated areas (Targett et al., 
1996), thus it is necessary to recruit oligodendrocytes progenitor cells (OPCs) to the 
demyelinated area. These OPCs differentiate into pre-myelinating oligodendrocytes 
and then form processes which are wrapped around the demyelinated axon. A 
possible explanation for the failure of remyelination in later stages after repeated 
cycles of demyelination and remyelination is the depletion of the OPCs (Trapp et al., 
1998). Since the OPCs have to be recruited into the demyelinated area, failure of 
recruitment can also be a cause for failure of remyelination even in the presence of 
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sufficient numbers of OPCs in the neighbouring areas (Franklin, 2002). The fact that 
some chronic lesions contain sufficient numbers of OPCs but are still demyelinated 
led to the hypothesis that the OPCs fail to differentiate and build a myelin sheath. In 
tissue of MS patients, cells of the oligodendrocytes-lineage were identified but these 
cells were quiescent, apparently unable to differentiate into remyelinating 
oligodendrocytes (Wolswijk, 1998). Axons play a role in proliferation, survival and 
differentiation of oligodendrocytes (Bozalli and Wrabetz, 2004). A shift in surface 
molecules on chronically demyelinated axons might render them unreceptive to 
remyelination or lead to a lack of differentiation triggers for the oligodendrocytes 
(Chang et al., 2002). It has been proposed that remyelination protects axonal 
integrity due to trophic support and protection against an inflammatory environment 
(Kornek et al., 2000). 
2.3 Neurodegeneration in Multiple Sclerosis 
Axonal injury in MS lesions was described by Charcot at the end of the 19th century 
(Charcot, 1868) but the development of inflammatory models of demyelination and 
some success of steroids in the treatment of relapses in MS patients shifted attention 
towards immune-mediated demyelination (Wilkins and Scolding, 2008) and the 
importance of axonal pathology was ignored for many decades. Interest in axonal 
pathology was renewed when MRI and post-mortem studies revealed that axonal 
destruction starts early during the disease course (Ferguson et al., 1997; Kuhlmann 
et al., 2002; Schirmer et al., 2009) and that it correlates strongly with the severity of 
disability in patients (De Stefano et al., 1998; Bjartmar and Trapp, 2003; Schirmer et 
al., 2011). Extensive loss of axons can be seen in acute demyelinating lesions but 
this lesion state usually only lasts for a few weeks. As mentioned before the brain 
has the ability to compensate for axonal loss to a certain degree and it is unlikely that 
the axonal loss in acute lesions exceeds this threshold (Dutta and Trapp, 2011), 
accounting for the fact that disabilities at this stage are still reversible. Chronic 
demyelinated lesions on the other hand can persist for years and over time slow, 
ongoing axonal loss is thought to make a major contribution to overall axonal loss 
which ultimately exceeds the brains compensatory capacity and leads to irrversible 
neurological disability. This would explain the transition from RRMS to SPMS and 
also the slow but steady accumulation of disabilities in progressive forms of MS. 
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Axonal loss in acute demyelinating lesions correlates with the inflammatory response 
(number of T-cells and macrophages) (Ferguson et al.,1997; Trapp et al., 1998) and 
activated immune and glial cells release a number of substances, including 
proteolytic enzymes, matrix metalloproteases, nitric oxide and cytokines (Hohlfeld et 
al.,1997; Trapp and Nave, 2008) which can damage axons. Glutamate toxicity can 
also contribute to axonal loss, by damaging oligodendrocytes. Neurodegeneration 
cannot only be observed in the highly inflammatory conditions of the acute 
demyelinating lesion but also in normal-appearing white matter (NAWM) in the 
absence of demyelination (Bitsch et al., 2000; Kornek et al., 2000). Studies show that 
activated microglia are associated with formation of lesions in the NAWM (De Groot 
et al., 2001; van der Valk & Amor, 2009) and that their activation cen be seen prior to 
demyelination and infiltration with T-cells (Barnett and Prineas, 2004; Gay et al., 
1997).  
In recent years neurodegeneration in the retina of MS patients has become a focus 
of research. It has been shown that atrophy of the retina is associated with total brain 
weight (Green et al., 2010), and thinning of the retinal nerve fibre layer (RNFL) 
correlates with white matter atrophy (Gordon-Lipkin et al., 2007) suggesting that 
retinal pathology might reflect occurance of neurodegeneration on a more global 
level and may be considered as a surrogative marker for brain atrophy. Thinning of 
the RNFL where the unmyelinated part of the axons of the RGCs is located and 
macular thinning has been shown in patients with MS and optic neuritis (Trip et al., 
2005; Fisher et al., 2006; Henderson et al., 2010). In addition, in patients not affected 
by optic neuritis thining of the RNFL can also be observed (Fisher et al., 2006; 
Pulicken et al., 2007; Henderson et al., 2008) as well as macular thinning and 
reduced ganglion cell layer thickness (Henderson et al., 2008, Syc et al., 2011). 
Retinal autopsy material confirmed RNFL thinning and loss of RGCs, but also 
revealed cell loss in the inner nuclear layer (where bipolar, horizontal and amacrine 
cells are located) (Green et al., 2010). It has been proposed that retinal pathology 
could occur as a primary event, independent from optic neuritis. A subset of patients 
has been described in which the macula rather than the RNFL or optic nerve are 
affected (Saidha et al., 2011), suggesting that neurons can be targeted primarily, 
without involvement of optic nerve pathology. The mechanism by which primary 
retina pathology occurs is unclear but involvement of reactive astrocytes and 
activated microglia is implicated by their presence in the retina (Green et al., 2010).  
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2.4 Experimental autoimmune encephalomyelitis – an animal model of 
MS  
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple 
sclerosis that mirrors many different aspects of the disease. The origins of EAE go 
back to the 1920s when spinal cord inflammation was induced in rabbits by 
inoculation with human spinal cord (Gold et al., 2006).  
The benefit of this model can be seen in the fact that three of the most commonly 
used therapies for MS have been developed in an animal model of EAE. For 
example, an antibody against α4β1 integrin was found to prevent EAE in Lewis Rats 
(Yednock et al., 1992) and was approved for MS treatment under the trademark 
name Natalizumab in 2004 (Steinman, 2005). After three patients developed 
multifocal leukoencephalopathy Natalizumab was withdrawn from the market but it 
has been reinstalled in 2006. Another therapy that has been successful in both the 
animal model and MS patients is mitoxantrone. It was shown that mitoxantrone 
suppressed clinical symptoms of EAE in Lewis rats (Ridge et al., 1985) and it has 
been approved for treatment for RRMS, SPMS and PRMS in 2000 (Hartung et al., 
2002). Copolymer 1, better known as glatiramer acetate (GA) was originally tested as 
an inducing agent for EAE. It did not induce EAE but actually prevented its symptoms 
(Teitelbaum et al., 1971). It was shown that GA reduces the relapse rate in RRMS 
(Johnson et al., 1995) and it was approved for treatment of RRMS in 1996. 
EAE can be induced in a variety of animals, mice, rats and guinea pigs are most 
common but EAE can also be induced in rhesus monkeys, macaques and the 
common marmoset (´t Hart et al., 2000). The advantage of monkey models is the 
rather close relationship between monkeys and humans. An advantage of using mice 
is the possibility of creating knock-outs to determine the role of specific molecules in 
the disease course. However in mice there is little demyelination and also the fact 
that B-cell deficient knock-out mice develop EAE that is very similiar to EAE in 
wildtype mice questions the importance of B-cells and autoantibodies for primary 
demyelination in the mouse model of EAE (Hjelmström et al., 1998). Since B-cells 
and antibodies play an important role in MS, the rat model is more suitable to 
examine this part of the disease since some rat models of EAE mimic this aspect 
very well. 
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The induction of EAE can be separated into three groups: spontaneous EAE, 
adoptive transfer EAE (AT-EAE) and actively induced EAE. There are no natural 
occurring models of spontaneous EAE but there are several transgenic mice strains 
that can spontaneously develop EAE (Wekerle, 2008). Mice that express MBP-
specific T-cells receptors can develop spontaneous EAE at variable rates, depending 
on the hygiene level of the breeding facility (Goverman et al., 1993). 
In AT-EAE myelin-specific T-cells are obtained from immunised animals and injected 
into healthy recipients which then develop symptoms of EAE. In the first succesful 
attempt of transferring EAE from one rat to another, lymph cells from immunised 
animals caused EAE in the recipients between day 11 and 19 after injection 
(Paterson, 1960). The role of T-cells in the induction of the disease became clear 
when the adoptive transfer of MBP-specific T-cells induced EAE in naive animals 
(Ben-Nun et al., 1981). It has to be noted that AT-EAE in rats is not a complete 
model of MS. It is an inflammatory disease with a monophasic course and only very 
little demyelination. Although T-cells play a key role in the breakdown of the blood-
brain-barrier and pathogenesis of EAE, this alone is insufficient to trigger extensive 
demyelination and chronic disease activity in rats, which are characteristic hallmarks 
for the human disease (Gold et al., 2006). This makes AT-EAE a suitable model to 
examine the pathogenesis of T-cell mediated inflammation in the CNS but in order to 
also examine B-cell and antibody response and subsequent demyelination, another 
model is more suitable: In actively induced EAE the animals are injected with either 
myelin basic protein (MBP), proteolipid protein (PLP) or MOG which are all proteins 
of the myelin sheath. MBP and PLP induce an encephalitogenic T-cell response in 
different rat strains with weak antibody response and only little demyelination (Gold 
et al., 2006). The induction of EAE with MOG on the other hand can also include a 
severe demyelinating autoantibody response depending on the rat strain used.  
The RT1 haplotypes which are analogue to the MHC in humans differ between 
different strains of rats. Brown Norway rats have the RT1n type and Lewis rats the 
RT1l type. In a comparison between the two strains it was shown that Brown Norway 
rats, which are resistant against purely T-cell mediated autoimmune diseases but 
very susceptible to autoantibody-mediated disease, exhibit a more severe course.  
The fact that the haplotype modulates the MOG-specific autoantibody response 
makes it clear that the B-cell mediated autoantibody response plays an important role 
in disease severity and susceptibility (Stefferl et al.; 1999). Since the MH complex 
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also plays a role in MS where several genes within the complex have been 
associated with higher susceptibility for MS this is another similarity between MS and 
EAE. Besides similarities in demyelination patterns between MS and MOG-induced 
EAE a comparative study of axonal loss in active, inactive and remyelinating lesions 
in MS patients and rats with MOG-induced EAE showed a strong resemblance in the 
axonal pathology (Kornek et al., 2000), suggesting that MOG induced EAE is very 
suitable model to investigate pathological features of MS.  
In this study the model of MOG-induced EAE in Brown Norway rats was used, 
focussing on optic neuritis. Around 65 % of all MS patients develop at least one 
episode of optic neuritis at some point and 15 to 20 % of MS cases first present with 
an episode of optic neuritis (Arnold, 2005). The 15 year risk to develop MS after an 
episode of optic neuritis lies between 25% and 72% correlating with the occurrence 
of white matter lesions at the same time (The Optic Neuritis Study Group, 2008). It 
has been previousley demonstrated that optic neuritis occurs in 80 to 90 % of MOG-
immunised Brown Norway rats (Meyer et al., 2001) and leads to axonal degeneration 
and loss of RGCs (Hobom et al, 2004; Diem et al.; 2005a). The anatomical 
organisation of the visual system with the cell bodies of RGCs located in the retina 
and their axons which comprise the optic nerve allows a separate examination of 
neurodegenerative events in cell bodies and axons. As mentioned above optic 
neuritis is a common first symptom, demonstrating an early manifestation of the 
disease in humans and in the Brown Norway rat model and thus giving the latter a 
great potential to understand early neurodegenerative changes.  
 
 
2.5 Apoptotic pathways in RGCs 
In MS and EAE lesions, transection and swelling of axons as well as disturbed 
axonal transport and changes in cytoskeletal proteins can be observed (Zhu et al., 
1999; Wujek et al., 2002; Trapp et al., 1998; Meyer et al., 2001) and are thought to 
be responsible for secondary apoptosis of cell bodies, including that of RGCs (Diem 
et al., 2005a). During development, apoptosis is needed to acquire the correct 
number of neurons since most classes of neurons produce more cells than needed 
during development (Bähr, 2000). After that initial period during development 
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neurons have to be maintained for the entire life and in the adult CNS their 
irreversible loss due to apoptosis contributes to clinical symptoms for example in 
neurodegenerative diseases and trauma. Apoptosis of neuronal cell bodies can be 
observed after traumatic axonal injury (Garcia-Valenzuela et al.; 1994; Isenmann et 
al., 1997; Diem et al., 2001) and despite strong differences concerning the trigger of 
the axonal injury, degeneration of RGCs shares common apoptotic pathways in 
axotomy models and under autoimmune inflammatory conditions. These include 
changes in proteins of the Bcl-2 family and the PI3K/Akt pathway and involvement of 
caspase 3. The Bcl-2 family contains pro-apoptotic proteins such as Bax, Bad, Bim 
and Bid and anti-apoptotic proteins such as Bcl-2, Bcl-XL and Bcl-W (Korsmeyer, 
1999). Overexpression of the anti-apoptotic protein Bcl-XL inhibits release of 
cytochrome c from the mitochondria (Kharbanda et al., 1997) and local protein 
delivery promotes RGC survival during EAE (Diem et al., 2005b). Overexpression of 
anti-apoptotic Bcl-2 in mice leads to resistance of RGCs to cell death after axotomy 
and ischemia (Martinou et al, 1994; Cenni et al.; 1996) and resistance against MOG-
induced EAE (Offen et al., 2000). Pro-apoptotic members of the Bcl-2 family such as 
Bax promote cytochrome c release which together with Apaf1 forms the apoptosome. 
Pro-caspase 9 is recruited to the apoptosome and activated. Active caspase 9 then 
activates other caspases such as caspase 3. Bax ablation reduces axonal damage in 
mice with EAE (Lev et al., 2004): And siRNA against Bax and Bax knockout reduces 
RGC death after optic nerve axotomy in mice (Lingor et al., 2005; Goldenberg-Cohen 
et al., 2011). After axotomy, a decrease in anti-apoptotic Bcl-2 and an increase in 
pro-apoptotic Bax can be found (Isenmann et al., 1997), and the same can be 
observed during optic neuritis, preceding the loss of RGCs (Hobom et al., 2004). 
Axotomy of the optic nerve leads to an increase in caspase 3 activity and DNA 
fragmentation, visualized with TUNEL staining (Kermer et al., 1999) which can also 
be observed in RGC death during optic neuritis (Meyer et al.; 2001). 
Another important mechanism in the regulation of apoptosis after axotomy and during 
optic neuritis is the the PI3K/Akt pathway. The phosphorylation of Akt via 
Phosphoinositide 3-kinase (PI3K) is reduced in RGCs after optic nerve transection 
(Kermer et al., 2000) and also during optic neuritis (Hobom et al., 2004). Phospho-
Akt can phosphorylate, and thereby inhibit the pro-apoptotic proteins Bad and 
caspase 9 (Datta et al.; 1997; Cardone et al.; 1998) which leads to decreased levels 
of caspase 3 (Li et al.; 1997). Therapies which increase the amount of phospho-Akt, 
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including TNF- alpha, erythropoietin and insulin growth factor-I (IGF-I), lead to 
increased RGC survival after axotomy and during optic neuritis (Weishaupt et al.; 
2004; Kermer et al., 2000; Diem et al., 2001; Sättler et al., 2004). In addition to the 
apoptotic death of RGCs after onset of clinical symptoms, death of RGCs can also be 
observed prior to clinical symptoms in a model of MOG-induced EAE in Brown 
Norway rats (Hobom et al., 2004) but the mechanism of this early degeneration of 
RGCs has not been elucidated yet. 
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Figure 2.1 Apoptotic and survival pathways of RGCs after axotomy and during optic neuritis 
Axotomy of the optic nerve as well as optic neuritis leads to death of RGCs via similar pathways. 
Changes in proteins of the Bcl-2 familiy can be observed, namely downregulation of anti-apoptotic Bcl-
2 and upregulation of Bax. Bax is thought to build a pore through which cytochrome c can be released 
from the mitochondria. The formation of this pore is inhibited by the anti-apoptotic protein Bcl-2. 
Ablation of Bax and overexpression of Bcl-2 and Bcl-XL promotes survival of RGCs. Cytochrome c 
forms the apoptosome together with Apaf-1, activating caspase 9 which then activates caspase 3. 
Increased activity of caspase 3 can be seen both after axotomy and during optic neuritis.  
Treatment studies show that phosphorylation of Akt protects RGCs in axotomy and optic neuritis. 
Phospho-Akt phosphorylates caspase 9 which than no longer is able to be a part of the apoptosome 
and also phoshporylates and thus inactivates the pro-apoptotic protein Bad. 
 
2.6 Calcium influx in neuronal and axonal degeneration  
Dysregulation of calcium homeostasis has been observed in several 
neurodegenerative diseases such as ALS, Parkinson´s disease and Huntington´s 
disease as well as in stroke and traumatic brain injury (TBI) (reviewed in Marambaud 
et al., 2009 and Wojda et al., 2008) and several studies show involvement of calcium 
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in axonal degeneration in trauma (George et al., 1995), anoxia (Imaizumi et al., 1999) 
ischemia (Stys et al., 2005) and inflammatory models (Kornek et al., 2001). 
Excessive calcium influx can be caused by several mechanisms, including sodium 
influx and subsequent influx of calcium through voltage dependent calcium channels 
(VDCCs) and the Na+/Ca2+ exchanger (NCX) (Figure 2.4). In normal axons the 
voltage-gated sodium channels Nav 1.2 and 1.6 are mostly restricted to the node of 
Ranvier. After demyelination of the axon, sodium channels are redistributed along the 
whole axon (Waxman et al., 2004) as an attempt to re-establish conduction. The 
redistribution of the sodium channels along the axons leads to a higher energy/ATP 
demand because action potentials are now accompanied by higher sodium influx and 
more energy is needed to keep the resting potential and sodium concentration within 
the normal range. ATP-depletion as a result of increased energy demand and 
mitochondrial dysfunction (Dutta et al., 2006) can induce failure of the 
sodium/potassium ATPase (Na/K-ATPase) and thus cause elevated sodium levels in 
the cell. The blockade of sodium channels with phenytoin proved to be 
neuroprotective for both RGCs and their axons in a glaucoma model (Hains and 
Waxman, 2005) and for spinal cord axons in a mouse model of EAE (Black et al. , 
2006), suggesting a role for sodium influx in neurodegeneration. The influx of sodium 
leads to depolarisation of the membrane and activation of voltage dependent calcium 
channels (VDCC). In both MS patients and rats with EAE, accumulation of the pore-
forming subunit of N-type voltage-gated calcium channels could be found along the 
axon colocalising with APP (Kornek et al., 2001), suggesting a role for these 
channels in axonal degeneration. This hypothesis is further strengthend by the fact 
that treatment with the N-type calcium channel blocker conotoxin reduces axonal 
damage in EAE (Gadjanski et al., 2009). In spinal cord axons of MS patients and 
EAE rats a co-localization of sodium channels with the NCX was found. The 
exchanger normally pumps three sodium ions into the cell in exchange for pumping 
out one calcium ion. Elevated sodium concentrations as well as membrane 
depolarisation can cause the NCX to go into reverse mode and thus lead to elevated 
calcium concentrations in the cell (Yu and Choi, 1997). Blockade of the NCX proved 
to be neuroprotective in axons following spinal cord white matter injury in rats (Li et 
al., 2000) and attenuated calcium influx and subsequent neurodegeneration in 
cultured hippocampal neurons (Araujo et al., 2007).  
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Another source for elevated intracellular calcium levels are ionotropic glutamate 
receptors which can be found on the cell body. Glutamate is the major excitatory 
neurotransmitter in the CNS (Curtis and Johnston, 1974; Fonnum, 1984). It has long 
been known that excessive or prolonged exposure to glutamate leads to neuronal 
degeneration, including degeneration of inner retinal layers such as the ganglion cell 
layer (Lucas and Newhouse, 1957; Olney, 1969; Sisk and Kuwabara, 1985) and that 
a rise in intracellular calcium concentration is a key component in glutamate-induced 
(excitotoxic) degeneration of neurons (Sucher et al., 1997; Sattler and Tymianski, 
2000). There are three classes of ionotropic glutamate receptors, named after their 
selective agonists: N-methyl D aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and kainate receptors. Binding of glutamate or the 
specific receptor agonists leads to opening of the pore and subsequent influx of ions 
such as sodium and calcium. Rodent RGCs express NMDA, AMPA and kainate 
receptors as was shown with electrophysiological recordings (Aizenman et al. 1988; 
Taschenberger et al. 1995; Karschin et al., 1988) and with single cell molecular 
profiling with RT-PCR (Jakobs et al., 2007). AMPA and kainate receptors usually 
have low calcium permeability (Hollmann et al., 1991; Burnashev et al., 1992; 
Sommer et al., 1991). NMDA receptors on the other hand are highly permeable to 
calcium (Mayer and Westbrook; 1987) and exposure to NMDA causes loss of cells in 
the inner retina layer (Siliprandi et al., 1992; Lam et al., 1999) implying an important 
role for these receptors in glutamade-mediated toxicity. Blocking the NMDA receptor 
with the specific antagonist (+)-5-methyl-10,11-dihydro-5H-dibenzo[a, d]cyclohepten-
5, 10-imine (MK801) reduces glutamate-induced cell death in cultured RGCs (Pang 
et al., 2007) and also leads to reduced calcium influx in cultured RGCs (Hartwick et 
al., 2008). Their study suggests an important role for NMDA receptors in excitotoxic 
degeneration of RGCs, whereas they suggest that activation of AMPA and kainate 
receptors results mainly in cell depolarisation, resulting in the release of the Mg2+ 
block of the NMDA receptors, therefore only making a minor contribution to calcium 
influx. These results suggest NMDA receptors as a suitable target for blocking 
experiments to examine the role of calcium influx via ionotropic glutamate receptors 
in the retina and as a potential method to protect RGCs against glutamate-induced 
neurodegeneration.  
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Figure 2.3 Calcium entry pathways  
The redistribution of sodium channels (Nav 1.6) along the axon (following demyelination) leads to an 
elevated intracellular sodium concentration. The redistribution also leads to a higher energy demand 
because action potentials now cause higher sodium influx and more ATP is needed to keep the 
resting potential and sodium concentration within normal range. ATP-depletion can induce failure of 
the sodium/potassium ATPase (Na/K-ATPase) and thus elevate sodium levels in the cell further. This 
causes depolarisation which activates VDCCs and thus leads to accumulation of calcium in the cells. 
The elevated sodium concentration also drives the sodium-calcium exchanger (NCX) into reverse 
mode which also contributes to elevated intracellular calcium concentration. Binding of glutamate to 
the ionotropic glutamate receptors (mainly NMDA but also AMPA/kainate) causes calcium influx. 
2.7 Manganese-enhanced MRI (MEMRI)  
MRI is an important tool to assess MS- or EAE-related pathological changes 
including inflammation, scar formation and atrophy. In patients with clinically defined 
MS, brain MRI imaging reveals multifocal cerebral white matter (WM) lesions in more 
than 95 % of patients (Inglese, 2006) and MRI features for dissemination in space 
and time have been incorporated within the diagnostic criteria for MS in 2001 
(McDonald et al., 2001).  
Using contrast agents allows better visualisation of anatomical structures but it can 
also be used to measure disease activity. Gadolinium enhancement for example is 
believed to be a highly sensitive marker for disease activity. Gadolinium cannot cross 
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the BBB under normal circumstances and enhancement implies a disruption of the 
BBB (Ding et al., 2006), which can be found in active lesions in MS. Manganese (in 
the form of MnCl2 or Mangafodipir Trisodium (MnDPDP)) is another contrast agent 
used in MRI. The paramagnetic ion reduces the spin-lattice relaxation time constants 
(T1) of tissues in which it has accumulated and thus causes positive contrast 
enhancement in T1-weighted MRI. The manganese ion (Mn2+) has been used as a 
tracer for calcium influx, as it is well established that it can enter cells via calcium 
transport mechanisms such as the sodium/calcium exchanger and voltage-
dependent calcium channels (VDCC) due to its similar size and ionic properties (Lin 
and Koretsky; 1997; Takeda, 2002). Experiments in MOG-induced EAE in Brown 
Norway rats have established that signal enhancement in the optic nerve can be 
seen after onset of clinical symptoms. The question if manganese enhancement in 
the optic nerve can already be seen during the induction phase of EAE has not yet 
been answered. 
Since the death of RGCs is an early finding in MOG-induced EAE in Brown Norway 
rats, manganese enhanced MRI of the retina could help to elucidate the role of 
calcium influx in RGC degeneration. Studies show changes in manganese uptake in 
the rat retina after insults such as increased intraocular pressure (Berkowitz et al., 
2008) and also an increase in manganese uptake correlating with decreased light 
exposure (Berkowitz et al. 2009).  
As mentioned above the NMDA-receptor blocker MK801 is known to reduce calcium 
influx in RGCs in vitro (Hartwick et al., 2008). MK801 is also able to cross the BBB 
(Clineschmidt et al., 1982), which makes it suitable for examining the role of NMDA 
receptors in manganese enhancement and thus calcium influx at early time-points. 
2.8 The calcium-activated protease calpain 
Elevated intracellular calcium concentration leads to the activation of different 
enzymes, one of which is the cysteine protease calpain. When activated calpain 
cleaves cytoskeletal proteins, for example ankyrin and members of the spectrin 
family such as α2-spectrin and β4-spectrin (Hall et al., 1987; Siman et al., 1984, 
Lövfenberg and Backmann, 1999; Schafer et al., 2009). These cytoskeletal proteins 
are important for maintaining membrane integrity and to restrict difussion of 
transmembrane proteins (Bennet and Gillian, 1993; Czogalla and Sikorski, 2005). 
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Breakdown products from α2-spectrin are commonly used as indicator for caspase 
and calpain activity. Caspase cleaves α2-spectrin into two fragments of 150 and 120 
kDa and calpain cleaves them into fragments of 150 and 145 kDa. The two best 
characterized members of the calpain family are µ-calpain and m-calpain which are 
expressed ubiquitously. They differ from each other in the amount of calcium that is 
needed for activation: m-calpain needs 0.2-0.8 mM whereas µ-calpain requires 2-80 
µM calcium (Camins et al., 2006). Under physiological conditions the calcium 
concentration is in the nanomolar range and only slight proteolytic modification of 
calpain substrates can be found. When the calcium concentration in the cells rises, 
more calpain is activated which leads to increased spectrin proteolysis. In 
hippocampal neurons stimulation of NMDA receptors leads to increased proteolysis 
(Seubert et al., 1988), whereas inhibition of proteases reduced the concentration of 
spectrin breakdown products (SBDP) in hippocampal neurons and promoted their 
survival (Lee et al., 1991). After onset of EAE, the calpain activity has been shown to 
rise, and might contribute to demyelination since it can cleave MBP and MOG 
(Schaecher et al., 2001; Shields and Banik, 1999). In an animal model of TBI calpain-
specific MBP breakdown products were found (Liu et al., 2006), suggesting a role for 
calpain in demyelination in vivo. Calpain is known to cause neurofilament breakdown 
in anoxic and ischemic optic nerves in rats (Stys and Jiang, 2002), which could 
contribute to axonal pathology. Activation of calpain also leads to internalisation of 
the plasma membrane Ca2+ ATPase (PMCA) (Pottorf et al., 2006) and cleavage of 
NCX (Bano et al., 2005) which leads to prolonged elevated calcium levels. 
Calpain is also involved in the apoptotic pathway. Calpain cleavage activates the 
protein phosphatase calcineurin which desphosphorylates the pro-apoptotic protein 
Bad. The dephosphorylated Bad forms a heterodimer with the anti-apoptotic proteins 
Bcl-2 and Bcl-XL (Hara and Snyder, 2007) and inactivates them. In a model of 
glaucoma the inhibition of calcineurin prevented cytocrome c release and death of 
RGCs (Huang et al., 2005). Calpain-mediated cleavage of the pro-apoptotic proteins 
Bid and Bax leads to cytochrome c release from mitochondria and activation of the 
caspase 3 dependent apoptotic pathway. In cultured NIH 3T3 cells calpain inhibition 
increased Akt phosphorylation and cell viability and it has been proposed that calpain 
activity inhibits phosphorylation of Akt by interacting with PI3K (Beltran et al., 2011). 
Cleavage of the cyclin-dependent kinase 5 (CDK5) activator p35 by calpain leads to 
deregulation of CDK5 and subsequent hyperphosphorylation of tau which has been 
    
26 Introduction 
proposed to be neurotoxic (Azuma and Shearer, 2008). In addition, it has been 
shown that calpain inhibitors reduce processing of p35 and death of cultured RGCs 
(Nath et al., 2000; Verdaguer et al., 2005).  
Taken together these results show that calpain plays an important role in 
neurodegeneration in different models and via different pathways. The role of calpain 
in our model and the time course of calpain activation have not yet been examined 
and it remains to be seen how it correlates with axonal degeneration and death of 
RGCs. 
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Figure 2.4 The role of calpain in apoptosis and axonal damage 
Calpain can cleave cytoskeletal proteins such as neurofilaments, spectrin and ankyrin. Calpain can 
also cleave the plasma membrane Ca2+ ATPase (PMCA) and the Na+/Ca2+ Exchanger (NCX) and thus 
contribute to prolonged elevated calcium levels. The activation of calcineurin via calpain-mediated 
cleavage inactivates anti-apoptotic proteins. Calpain cleavage also activates pro-apoptotic proteins 
which lead to cytochrome c release and subsequent caspase 3 activation and apoptosis. Calpain-
mediated deregulation of the cyclin-dependet kinase 5 (CDK5) leads to hyperphosphorylation of tau 
which then forms tangles, causing disturbed transport. By interacting with the PI3 kinase calpain 
causes reduced phosphorylation of Akt, which also contributes to apoptosis. 
 
2.9 Calpain activity as therapeutic target  
As discussed above, activation of calpain plays an important role in apoptotic 
processes and axonal damage. Recently it was shown that calpain inhibition with 
calpeptin reduces CCL2 induced chemotaxis in T-cells (Butler et al., 2009). 
Pretreatment of MBP-specific T-cells with calpeptin before adoptive transfer leads to 
reduced clinical symptoms and reduced inflammation, demyelination and axonal loss 
in the spinal cord in mice (Guyton et al., 2009) and treatment with calpeptin also 
reduces clinical symptoms, inflammation, demyelination and axonal loss in the spinal 
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cord of Lewis rats with EAE (Guyton et al., 2010). Treatment of cultured RGCs with 
calpeptin reduces apoptosis after ionomycin-induced calcium influx (Das et al., 
2006). Treatment with calpeptin could therefore prove to be beneficial in reducing 
severity of optic neuritis by reducing inflammatory infiltration and may decrease 
degeneration of RGCs by attenuation of apoptosis. 
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Aim of the study 
The research in MS has been traditionally focused on understanding the role of 
inflammation. However, in recent years neurodegeneration has emerged as an 
important research area, due to an increasing amount of evidence that 
neurodegeneration is an early event in the disease, occurring from the onset and is 
also probably the main determinant of permanent clinical disability.  
In the model used in this study early neurodegeneration can be observed in the 
RGCs but the relationship with the immune response is unclear since degeneration is 
observed prior to onset of inflammatory infiltration of the optic nerve and subsequent 
axonal injury. This raises the question if subtle axonal changes or changes in the 
retina itself could contribute to early neurodegeneration and which mechanisms are 
involved in the early death of RGCs. It has been shown that calcium influx and 
subsequent calpain activation can cause neuronal and axonal damage and increased 
calcium influx during the clinical phase of EAE has already been proven. The 
questions if calcium influx in the optic nerve already starts in the induction phase of 
the disease and if early calcium influx in the retina and subsequent activation of 
calpain could be a possible mechanism for early death of RGCs were examined in 
this study since they have not yet been adressed. Since neurodegeneration is now 
thought to be a main contributor to permenant clinical disability in patients, 
neuroprotective strategies have become a focus of research. This study adresses the 
question if inhibition of calpain activation could prove beneficial for RGC survival both 
during the induction and clinical phase of EAE. 
    
30 Material and Methods 
3 Material and Methods 
3.1 Animals 
Female Brown Norway rats 8–10 weeks of age were used in all experiments. They 
were obtained from Charles River (Sulzfeld, Germany) and kept under 
environmentally-controlled conditions in the absence of pathogens. All experiments 
that involved animal use were performed in compliance with the relevant laws and 
institutional guidelines of the Saar-Pfalz Kreis. 
 
3.2 Induction and evaluation of EAE 
Whole recombinant MOG (Weissert et al., 1998) was used to induce MOG-EAE. 
Animals were anesthetized by inhalation of 5 % isoflurane and injected intradermally 
in the tail with a volume of 200 µl containing 100 µg of MOG (gift from Prof. D. 
Merkler, Department of Pathology and Immunology, University of Geneva) in 
phosphate-buffered saline (PBS, Sigma, St. Louis, USA) mixed (1:1) with complete 
Freund´s adjuvant (Sigma) containing 200 µg of heat-inactivated Mycobacterium 
tuberculosis (Difco Microbiology, Kansas, USA). Sham controls were immunised 
without MOG. 
Rats were scored daily for clinical signs of EAE. The following scoring system was 
used: grade 0.5: distal paresis of the tail; grade 1: complete tail paralysis; grade 1.5: 
paresis of the tail and mild hind leg paresis; grade 2.0: unilateral severe hind leg 
paresis; grade 2.5: bilateral severe hind limb paresis; grade 3.0: complete bilateral 
hind limb paralysis; grade 3.5: complete bilateral hind limb paralysis and paresis of 
one front limb; grade 4: complete paralysis (tetraplegia), moribund state, or death.  
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3.3 Retrograde labeling of RGCs  
One week before immunisation, rats were anaesthetized by intraperitoneal injection 
(i.p.) of ketamine 10 % (0.6 ml / kg; Serumwerk, Bernburg, Germany) and xylazine 2 
% (0.3 ml / kg; Riemser, Greifswald, Germany) and placed in a stereotactic frame. A 
mediosagittal incision was made and two holes were drilled in the skull, one above 
each superior colliculus (6.8 mm dorsal and 2 mm lateral from Bregma). The rats 
were then injected with 2 µl of the fluorescent dye Fluorogold (5 % in saline, 
Fluorochrome LLC, Denver, USA) into each superior colliculus using a 100 µl glass 
syringe (Hamilton, Reno, USA) at a speed of 0.75 µl / min. 
 
3.4 Quantification of RGC numbers  
At the end of experiments, rats received an overdose of ketamine 10 % (1 ml / kg) 
and xylazine 2 % (0.5 ml / kg) and were perfused via the aorta with 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS). The retinas were 
dissected and flat-mounted onto glass slides. They were examined with a 
fluorescence microscope (Nikon, Japan) using an UV filter (365/420 nm). RGC 
densities were quantified by two observers (second observer was Dr. Sarah 
Williams) by counting of labelled cells in 12 distinct areas of 62,500 µm2 each (three 
areas per retinal quadrant at three different eccentricities of 1/6, 1/2 and 5/6 of the 
retinal radius). 
 
3.5 Tissue preparation 
Animals were perfused via the aorta with 4 % PFA in PBS. The tissue was post-fixed 
in PFA overnight and 12 hours prior to dissection the tissue was placed in PBS. 
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3.5.1 Preparation of paraffin-embedded tissue and sections 
Optic nerves and spinal cord were removed and put in PBS. Tissue was then 
embedded in an automatic tissue processor (Leica, Wetzlar, Germany). After this, 
tissue was embedded in paraffin using a paraffin embedding machine (Leica). For 
optic nerves, embedding was performed in two different orientations to create both 
longitudinal and cross-sections. For spinal cords only cross-sections were created. 
For cross-sections, the optic nerves were cut into three pieces. After embedding in 
paraffin, blocks were cooled on a cooling plate and afterwards cut into 0.5 µm thick 
sections with a microtome (Leica) and placed on frosted slides (VWR, Darmstadt, 
Germany). 
 
3.5.2 Preparation of frozen tissue and sections 
For retinal sections, the cornea, vitreous body and parts of the sclera were removed. 
The eyes were cryoprotected in 30 % sucrose (AppliChem, Darmstadt, Germany) in 
PBS overnight. The tissue was placed in a base mold (Medite, Burgdorf, Germany) 
filled with optimum cutting temperature (OCT) compound (Medite) and then frozen by 
placing the base mold in isopenthane which was precooled in liquid nitrogen. Frozen 
tissue was kept at -80°C, and shortly before cutting the tissue was transferred to -
20°C. Retinas were cut into 18 µm thick sections using a cryostat (Fisher Scientific, 
Schwerte, Germany) with a chamber temperature of -25°C, placed on frosted slides 
(VWR) and then stored at -20°C. 
 
3.6 Histopathology 
3.6.1 Luxol Fast Blue 
To determine the extent of demyelination, 0.5 µm optic nerve (ON) cross- and 
longitudinal-sections were stained with Luxol Fast Blue (LFB). After deparaffinization 
in rothihistol (Roth, Karlsruhe, Germany), the sections were placed in 100 % and 96 
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% alcohol. Afterwards they were incubated overnight in 0.1% LFB solution in 96 % 
Ethanol with 0.1 % acetic acid (Solvent blue 38, Sigma, Steinheim, Germany) at 
60°C. On the second day the slides were cooled to room temperature (RT) and put in 
90 % alcohol. Then each slide was put individually into 0.05 % lithiumcarbonate 
solution (Fluka/Sigma) until the colour of the tissue changed from dark blue to 
turquoise. The slides were put in 70 % ethanol and then in water. Afterwards the 
slides were put in periodic acid (Sigma) for 10 minutes followed by 5 minutes in 
running tap water. The tissue was then incubated for 30 minutes in Schiff´s reagent 
(Sigma) and left under running tap water for 5 minutes for the blue colour to develop. 
A counterstain was performed with haematoxylin and then the tissue was dehydrated 
and mounted with Roti® - Histokitt II (Roth). 
Demyelinated areas were determined as a percentage of the whole ON cross-section 
area. The surface area of the ON was measured using the ImageJ software (NIH 
Image, http://rsb.info.nih.gov/ij/) 
 
3.6.2 Bielschowsky´s Silver Impregnation 
To determine the extent of axonal loss, ON cross-sections were stained with 
Bielschowsky´s silver impregnation. Sections were rehydrated and then incubated in 
20 % silver nitrate solution (Roth) for 20 mins. Following this, slides were then 
transferred to distilled water (dH2O) and ammonia (VWR) was added dropwise to the 
silver nitrate solution until it became clear. The slides were placed in the solution and 
incubated for 20 mins in the dark. Afterwards the developer was added dropwise until 
the tissue became brown. The stain was then fixed with 2 % sodium-thiosulfate 
(Fluka/Sigma) for 2 mins. Finally the sections were dehydrated and mounted with 
Roti® - Histokitt II. 
Axonal densities were determined semi-quantitatively with an eyepice graticule 
(Nikon, Japan). The unit area has 25 crosses and each point where an axon 
intersected the cross or the circle around it was counted as positive. Four unit area 
areas were randomly positioned within the area of the ON cross section. 
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3.7 Immunohistochemistry 
Paraffin-embedded sections were placed overnight at 60°C and then deparaffinized 
in Roti Histoclear (Roth) and hydrated in a decreasing series of alcohols. After 
washing in dH2O the slides were heated in a microwave in various antigen retrieval 
solutions (Table 2-2) and left to cool down for 15 minutes before washing in PBS. For 
the tissue to be treated with diaminobenzidine (DAB, Sigma) the endogenous 
peroxidase activity was quenched in 3 % H2O2 (Fischar, Saarbrücken, Germany) for 
10 minutes at RT, followed by washing in PBS. Tissue was blocked with 10 % serum 
/ 2 % bovine serum albumin (BSA, Sigma) in PBS for 20 minutes at RT. Afterwards 
the primary antibody was applied (Table 3-1 for details) and the tissue was incubated 
overnight at 4°C. 
Frozen retina sections were thawed for 10 minutes at RT and then washed in PBS 
for 3x5 minutes. The tissue was blocked for one hour in 20 % serum and afterwards 
the primary antibody was applied (Tabelle 3-2 for details) and the tissue was 
incubated overnight at 4°C.  
 
3.7.1 Light microscopy: 
Following washing in PBS, the appropriate secondary antibody was applied (Table 2-
3 for details) and left on the tissue for 1h at RT, followed by a further 3 washes in 
PBS. Then the tissue was incubated with ABC Elite Kit (Vector, Burlingame, USA) for 
1h at RT and coloured using either DAB or SG substrate (Vector) for 10 minutes at 
RT. The reaction was stopped by putting the slides in water (DAB) or PBS (SG) for 5 
minutes. 
When counterstaining was required, slides were put for 3 minutes in haematoxylin 
and then dipped in HCl-EtOH. Afterwards the tissue was dehydrated in increasing 
ethanol concentrations, placed in Roti Histoclear and then mounted with Roti® - 
Histokitt 
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3.7.2 Fluorescence microscopy 
Afther the secondary antibody was applied (Table 3-3 for details) the tissue was 
incubated for 1h at RT in the dark, followed by 3 washes in PBS. Tissue was 
mounted with Vectashield containing DAPI (4', 6-diamidino-2-phenylindole) (Vector). 
 
Table 3-1 Primary antibodies and antigen retrieval methods used for immunohistochemistry 
with paraffin sections 
Antibody ED1 PCNA CD3 EMAP II 
Company Serotec, UK Santa Cruz, USA Dako, Denmark Abcam, UK 
Antibody subtype mouse IgG1 mouse IgG2A rabbit polyclonal mouse IgG 
Antigen 
Retrieval 
(15 min) 
citrate buffer, pH 
6.0 
Antigen unmasking 
solution (Vector) 
EDTA buffer, 
pH 7.4 
citrate buffer,  
pH 6.0 
Blocking serum 
horse 
Vector 
horse 
Vector 
goat 
Sigma 
horse 
Vector 
Antibody 
concentration 
1:500 1:5000 1:600 1:600 
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Tabelle 3-2 Primary antibodies used for immunohistochemistry with frozen retina sections 
Antibody ED1 GFAP 
Company Serotec Sigma 
Antibody subtype mouse IgG1 rabbit polyclonal 
Blocking serum horse 
Vector 
goat 
Sigma 
Antibody concentration 1:400 1:400 
 
 
Table 3-3 Secondary antibodies for immunohistochemistry (DAB and fluorescence) 
Antibody Horse α Mouse 
biotinylated 
Goat α Rabbit 
biotinylated 
Goat α Mouse 
Cy3 
Goat α Rabbit 
Cy3 
Company Vector Vector Jackson Labs, USA Jackson Labs, USA 
Antibody subtype anti-mouse IgG anti-rabbit IgG anti-mouse IgG anti-rabbit IgG 
Blocking serum horse 
Vector 
goat 
Vector 
goat 
Sigma 
goat 
Vector 
Antibody 
concentration 
1:200 1:200 1:400 1:400 
 
3.7.3 Immunohistochemistry for β-amyloid precursor protein (APP) 
For APP staining, a modified protocol was necessary: 
Sections were deparaffinized overnight at 60°C and then rehydrated to 96 % ethanol 
before the endogenous peroxidase activity was quenched in 0.7 % H2O2 in methanol 
for 30 min. Afterwards the tissue were rehydrated further and then placed in distilled 
water for 5 min. The slides were then put in a steamer (Braun, Kronberg Germany) 
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with 0.2 % citrate buffer pH 6,0 (Merck) for one hour and then allowed to cool down 
for another hour. Afterwards the tissue was blocked with 20 % horse serum in 
antibody diluent (Dako, Glostrup, Denmark) for one hour at RT. Afterwards the 
primary antibody was applied and the tissue was incubated at 4°C overnight and then 
washed with PBS before adding the secondary antibody for one hour at RT. After 
washing the slides were then placed in Avidin solution (Sigma; 1:100) for one hour at 
RT and coloured with DAB substrate kit for peroxidase for 10 minutes. The reaction 
was stopped in distilled water. For counterstaining, tissue was incubated for 10 
minutes in haematoxylin, and then dipped in HCl-EtOH (Merck). Afterwards the 
tissue was dehydrated in increasing ethanol concentrations, placed in Roti Histoclear 
(Roth) and then mounted with Roti® - Histokitt II. 
3.7.4 Immunohistochemistry with two antibodies 
When tissue was stained with two different antibodies in combination, following the 
first set of primary and secondary incubations, sections were washed in PBS, 
blocked a second time in 10 % serum / 2 % BSA, and followed by the second set of 
antibodies. 
In order to control for the cross-reaction of antibodies in these double labelling 
experiments, the following controls were performed (Table 3-4). 
The results showed that each combination gave similar results. For further staining 
ED1 was used with DAB and PCNA with SG because PCNA positive and negative 
cells was easier to distinguish with SG staining. 
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Table 3-4 Controls performed for double staining 
Antibody Substrate 
ED1 DAB 
ED1 SG 
PCNA DAB 
PCNA SG 
1.ED1 
2.PCNA 
1.DAB 
2.SG 
1.ED1 
2.PCNA 
1.SG 
2.DAB 
1.PCNA 
2.ED1 
1.DAB 
2.SG 
1.PCNA 
2.ED1 
1.DAB 
2.SG 
 
3.8 Western Blot analysis 
For western blot analysis, rats were sacrificed by inhalation with CO2. Retinas and 
ONs were dissected and placed in ice cold lysis buffer (Roche, Mannheim, Germany) 
containing several protease inhibitors, and mechanically homogenized (Kontes, 
Vineland, USA). The lysates were sonicated for 5 seconds. Cell debris was pelleted 
at 13,000 rpm for 15 minutes at 4°C. For all western blots a minimum of three 
animals per time point were used. Supernatant protein concentrations were 
determined using a bicinchoninic acid (BCA)-based assay (Pierce, Rockford, USA). 
Proteins were then separated by reducing sodium-dodecyl sulfate -polyacrylamide 
gel electrophoresis (SDS-PAGE). Sample buffer (2x Tris Glycine SDS sample buffer, 
(Anamed Elektrophorese, Gross-Bieberau, Germany) was added to all samples prior 
to boiling at 95 °C for 10 minutes. Samples were loaded on a 10 % Tris Glycine gel 
(Anamed Elektrophorese), and electrophoresis was performed for 1.5 hours at 120 V 
in running buffer containing 25 mM Tris Base, 190 mM glycine and 0.1 % SDS in 
dH2O. Afterwards proteins were transferred to a nitrocellulose membrane (Whatman, 
Dassel, Germany) with either the wet blot technique at 100V for one hour at RT or 
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with the semi-dry blot technique at 200 mA for two hours at RT (Transfer buffer: 25 
mM Tris base, 192 mM glycine and 20 % MeOH). To confirm the transfer, the 
proteins on the membrane were stained with Ponceau (Sigma).  
Membranes were blocked for 1h at RT and, depending on the antibody, in either milk 
(Fluka/Sigma) or BSA (Sigma) in PBS with 0.1 % Tween 20 (PBS-T) (for details see 
Table 3-5), followed by incubation at 4°C overnight with the primary antibody: After 
washing with PBS-T for 30 min, Horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Table 3-6 ) were applied to the membranes and incubated for 
one hour at RT. To detect the labeled proteins the ECL-plus reagent (Amersham, 
Buckinghamshire, UK) was applied for one min. To quantify the western blot results, 
the intensity of the bands were measured with ImageJ software and divided by the 
intensity of the bands of the housekeeping proteins Glyceraldehyde-3-Phosphate 
Dehydrogenase (GAPDH) or actin.  
 
Table 3-5 Primary antibodies used for western blot analysis 
Antibody GAPDH Actin 
Spectrin 
BDPN 
Spectrin 
SBDP 
GFAP 
Company Chemicon, USA Chemicon, USA 
Bahr lab, 
USA 
Chemicon, USA Sigma 
Subtype 
mouse IgG1 mouse IgG1 
rabbit 
polyclonal 
mouse 
IgG1 
rabbit 
polyclonal 
Concentration 1:250 1:1000 1:300 1:1000 1:1000 
Blocking 
solution 
5% milk 
PBS-T 
5% milk 
PBS-T 
5% BSA 
PBS-T 
5% milk 
PBS-T 
5% milk 
PBS-T 
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Table 3-6 Secondary antibodies used for western blot analysis 
Antibody Donkey α Rabbit 
HRP-conjugated 
Sheep α Mouse 
HRP-conjugated 
Company Amersham, USA Amersham, USA 
Subtype anti-rabbit IgG anti-mouse IgG 
Concentration 1:5000 1:5000 
Blocking 
solution 
5% milk or BSA 5% milk or BSA 
3.9 Collection of cerebrospinal fluid 
Brown Norway rats were anaesthetized with intraperitoneal injection of ketamine 
10 % (0.6 ml / kg; Serumwerk, Bernburg, Germany) and xylazine 2 % (0.3 ml / kg; 
Riemser, Greifswald, Germany) and placed in a stereotactic frame. The skin was 
incised mediosagittally, and a hole was drilled into the skull at a 31° angle above the 
cisterna magna (2.7 mm dorsal from the intraaural line). Then a needle was placed 
on top of the hole and slowly lowered 7.2 mm. The needle then was lowered down in 
1 mm steps (up to 4 mm) to collect cerebrospinal fluid from the cisterna magna. Once 
obtained, the CSF was aliquoted and stored at -80°C.  
3.10 Serum collection 
After animals were sacrificed with CO2, blood was collected by heart puncture. Blood 
was coagulated overnight at 4°C, centrifuged at 4°C for 15 minutes at 13,000 rpm 
and the supernatant aliquoted and stored at -80°C. 
 
3.11 Enzyme Linked Immunosorbent Assay (ELISA)  
To determine the concentration of different cytokines, the neurodegenerative marker 
tau and anti-MOG antibodies in the serum and CSF the ELISA technique was used. 
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3.12 ELISA with serum samples 
In serum samples the titre of anti-MOG antibody was measured. Samples from 
healthy, sham immunised animals and MOG-immunised animals at different 
timepoints after immunisation and onset of clinical symptoms were measured, using 
the following protocol: 
Whole recombinant MOG was diluted in PBS to a concentration of 5 µg / ml and 
100 µl of the solution was to coat each well of a 96 wells microtitre plate. The plate 
was then incubated overnight at 4°C. The next day the antigen solution was removed 
and the plate was washed three times with PBS containing 0.05 % Tween (PBS-T). 
For blocking, 200 µl of 5 % BSA in PBS was pipetted into each well and the plate 
stayed overnight at 4°C. The next day the blocking buffer was removed and the plate 
was washed four times with PBS-T. Serum samples were diluted to 1:100.000, 
1:250.000 and 1:500.000 and 100 µl of each dilution was added in duplicate to an 
antigen-coated well. After two hours incubation at RT, the samples were removed 
and the plate was washed four times in PBS-T. 100 µl of secondary goat anti-rat 
antibody (1:5000) in blocking buffer was added to each well and incubated for two 
hours at RT. The antibody solution was removed and the plate was washed four 
times with PBS-T. 100 µl per well of TMB (Sigma) was added and the reaction was 
stopped after 15 min by adding 0.16M H2SO4. Absorbance was measured at 450 nm.  
 
3.13 Multi-spot assays (collaboration with Prof.Dr. Markus Otto and his 
group) 
For the measurement of different cytokines and the neurodegenerative marker total 
tau/phospho-tau in the CSF, a different approach was necessary due to the small 
sample size. It is possible to measure several cytokines with one sample of 25 µl by 
using multi-spot 96 well-plates. In these plates the bottom of the wells is not coated 
with a single antigen but there are small spots (4, 7 or 10) coated with different 
antibodies. In Figure 3.1 is an example of a 7 spot plate which recognizes different 
cytokines. The cytokine plate and a plate for total tau/phosphor-tau (Meso Scale 
Discovery, Gaithersburg, USA) were analyzed on a Sector Imager 6000 (Meso Scale 
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Discovery). Concentrations in multispot ELISA assays were calculated with Graph 
Pad Prism (Graph Pad Software Inc., La Jolla, USA). 
 
 
 
Figure 3.1 Example of a 7 spot plate available for rat CSF 
The picture shows the bottom of one well of a 96 well multispot plate. Each well is coated with 7 spots 
with antibodies against different cytokines. With this technique one sample of 25 µl is sufficient to 
detect the concentration of 7 different cytokines. 
 
For the multi-spot assays the following protocols were used: 
 
7 spot cytokine assay: 
In each well of the cytokine plate 25 µl of rat serum cytokine assay diluent (RSC) 
were pipetted and the plate was incubated for 30 minutes at RT with vigorous 
shaking. By diluting the calibrator stock solution (MSD) in RSC a seven point 
calibration curve (0, 9.8, 39, 156, 625, 2500, 10.000 and 40.000 pg / ml) was 
prepared. Then 25 µl of CSF sample or calibrator were pipetted into the wells and the 
plate was incubated for two hours at RT on a tumbling table. The plate wash then 
washed 3 times with PBS-T and 25 µl of antibody detection solution (diluted to 
1 µg / ml in rat serum cytokine antibody diluent) were added to each well before the 
plate was incubated for one hour at RT on a tumbling table. The plate was washed 3 
times in PBS-T and 150 µl of 2x read buffer (diluted in dH2O) were added to each 
well. Immediately after adding the read buffer the plate was analysed with the Sector 
Imager 6000.  
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Multi-spot phosphor-tau/total tau assay: 
In each well of the cytokine plate, 25 µl of blocking solution A (3 % Blocker A in Tris 
Wash Buffer) were pipetted and the plate was incubated for 1h at RT with vigorous 
shaking and then washed with Tris Wash Buffer. By diluting the calibrator stock 
solution (MSD) in 10 % Blocker A in Tris Wash Buffer an eleven point calibration 
curve (0, 10, 30, 100, 300, 1000, 3000, 10.000, 30.000, 100.000, 300.000 and 
1.000.000 pg / ml) was prepared. Then 25 µl of CSF sample or calibrator were 
pipetted into the wells and the plate was incubated for one hour at RT on a tumbling 
table. The plate wash then washed 4 times with Tris Wash Buffer and 25 µl of 
antibody detection solution (diluted to 10 nM in antibody dilution buffer) were added 
to each well and the plate was incubated for one hour at RT on a tumbling table. The 
plate was washed 4 times with Tris Wash Buffer and 150 µl of 1x read buffer (diluted 
in dH2O.) were added to each well. To avoid bubbles in the wells the reverse 
pipetting technique was used in this step. Immediately after adding the read buffer, 
the plate was analysed with the Sector Imager 6000.  
 
3.14 Manganese-enhanced Magnetic Resonance Imaging (MEMRI) 
Animals underwent MRI prior to immunisation, on d3 p.i., d5 p.i., d7 p.i., d10 p.i. and 
d1 of EAE. Sham-immunised animals were used as controls. For each 
timepoint/parameter a minimum of three animals were investigated. 
Anaesthesia was induced with 4% isoflurane in oxygen at a rate of 2 l / min. The 
animals were placed in the MRI and anesthesia was maintained with 2 % isoflurane 
in 1l / min oxygen. All measurements were performed using a 9.4 Tesla Bruker 
Biospec Avance III machine and either a transmit/receive mouse body quadratur coil 
(for optic nerves) or a saddle-shaped surface coil with a 2x2 array setup (for retinas). 
Signal intensities were measured with Paravision (Bruker) and false colour images 
were made with image J. 
Different protocols were used for optic nerves and retinas: 
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Optic nerve protocols: 
To verify the correct positioning of the animal in the machine a tri-pilot scan was 
performed. For positioning of the scan area a T2-weighted sagittal Rapide Acquisition 
with Relaxation Enhancement (RARE) scan (TR/TE = 5000 ms / 57 ms) was 
performed and positioning was checked with a T2-weighted coronal RARE scan 
(TR/TE = 2300 ms / 39.6 ms). This scan was also used to monitor changes in the 
diameter of the optic nerve during the disease course. For measuring of manganese 
enhancement a T1-weighted 3D FLASH scan was performed with a TR/TE of 
25 ms / 4.3 ms. 
After acquisition of pre-contrast T1-weighted 3D FLASH images, animals were 
injected with 20 mg / kg MnCl2 dissolved in 1 ml saline at a rate of 100 µl / min. 
T1-weighted 3D Flash scans were then performed 10, minutes after MnCl2 injection 
and in some animals also 60 and 120 minutes and 24 hours after MnCl2 injection.  
 
Retina protocols: 
To verify the correct positioning of the animal in the machine a tri-pilot scan was 
performed. For positioning of the scan area a T2-weighted sagittal RARE scan 
(TR/TE = 5000 ms / 57 ms) was performed and positioning was checked with a 
T2-weighted coronal RARE scan (TR/TE = 2300 ms / 39.6 ms). For measuring of 
manganese enhancement a T1-weighted MSME scan (TR/TE = 320 ms / 9.1 ms) 
was performed. After acquisition of pre-contrast T1-weighted MSME images, animals 
were injected with 10 mg / kg MnCl2 dissolved in 1 ml saline at a rate of 100 µl / min. 
T1-weighted MSME scans were performed 10 minutes, one hour and two hours after 
injection. For blocking experiments healthy animals and animals at d5 p.i were 
injected with the NMDA receptor blocker MK 801 40 minutes prior to MnCl2 injection. 
The blocker was injected i.p. at a dosage of 2 mg / kg in 1 ml saline. The control 
group received an i.p. saline injection of the same volume.  
 
3.15 Treatment study with calpeptin 
Animals were Fluorogold-labelled one week prior to immunisation as described 
previously in 3.3. From the day of immunisation onwards, animals received i.p. 
injections twice daily with 250 µg / kg calpeptin (Santa Cruz, USA) in saline until they 
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were sacrificed on d5 p.i., d10 p.i., or d1 of EAE. Calpeptin was solved in DMSO at a 
concentration of 10 mg / ml. The control group received an equivalent volume of 
saline with DMSO twice daily. Animals were sacrificed on either d10 p.i. or d1 of EAE 
to count Fluorogold-labelled RGCs. Western blot was performed on animals 
sacrificed on day 5 p.i. to verify reduced calpain activity after calpeptin treatment by 
using an antibody against BDPN, as described in 3.8. Histopathological staining with 
LFB and Bielschowsky silver impregnation and immunohistochemistry with 
antibodies against CD3, ED1 and β-APP (as described in 3.6.1, 3.6.2, 3.7.1 and 
3.7.3) were performed on optic nerve sections at d1 of EAE to assess possible 
changes in severity of optic neuritis after calpeptin treatment. 
 
3.16 Statistical analysis 
Statistical significance of the data concerning changes in axonal and RGC densities, 
changes in demyelination, number of infiltrating cells, relative optical density in 
western blot bands and signal enhancement in MRI was assessed with the two-tailed 
t-test and two levels of significance were defined: *p ≤ 0.05 to be significant, 
**p ≤ 0.01 to be very significant. Error bars represent standard error of the mean 
(SEM). For all statistical analyses excel, version 2003, (Microsoft Office, Microsoft 
Corporation, USA) was used.  
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4 Results  
 
4.1 Disease course  
EAE is an animal model of multiple sclerosis that shares many aspects with the 
human disease, including inflammation and axonal loss. Brown Norway rats are 
known to be susceptible to antibody-mediated diseases and unlike in other rat strains 
immunisation with MOG causes severe demyelination of the optic nerve and a high 
incidence of optic neuritis (Meyer et al.; 2001)., also a common early symptom of MS, 
that leads to axonal degeneration and apoptotic death of RGCs (Diem et al.; 2005a), 
which makes them a suitable model to investigate neurodegenerative changes in a 
setting that closely resembles MS. 
After Brown Norway rats were immunised they were scored daily for clinical 
symptoms according to a clinical score (2.2 Induction and evaluation of EAE). The 
average day of onset was d17.25 ± 0.82 (n=17) following immunisation, with onset 
occurring between d10 and d23 p.i. 62.5% of the immunised animals developed 
clinical symptoms of EAE. 
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Figure 4.1 Time course of EAE 
After immunisation with MOG, animals where scored daily for clinical symptoms. The earliest onset 
was on d10 p.i., average onset was on d17 p.i. In the induction phase no clinical symptoms (which 
represent spinal cord involvement) could be seen. 
 
4.2 Loss of RGCs started during the induction phase 
In MS optic neuritis is often the first symptom and also many patients have at least 
one episode of optic neuritis during the course of their illness (The Optic Neuritis 
Study Group, 2008). The loss of RGCs can occur secondary to optic neuritis, 
expressing hallmarks of apoptotic death (Meyer et al.; 2001). To assess how early in 
the course of EAE neurodegeneration within the retina could be seen RGCs were 
labelled with fluorogold, a fluorescent dye. The majority of axons from RGCs project 
into the superior colliculi and when the dye is injected into the superior colliculi it is 
transported retrogradely into the cell body of RGCs (Simon and Thanos, 1998). The 
labelled RGCs were then counted in healthy animals and sham-immunised animals 
(Figure 4.2, A) and in MOG immunised animals at d5 p.i and d7 p.i. (Figure 4.2, B) 
and at d1 of EAE (Figure 4.2, C) and d8 of EAE (Figure 4.2, D). The numbers of 
RGCs per mm2 in sham-immunised animals were similar to those in healthy (1771.06 
± 85.07 cells / mm2 in sham-immunised animals and 1756.47 ± 121.17 cells / mm2 in 
healthy animals), which proves that the loss of RGCs is a MOG-specific event. The 
number of RGCs decreased significantly on d5 p.i (*p ≤ 0. 05) to 1474.83 ± 66.61 
cells / mm2 and to 1282.99 ± 57.09 cells / mm2 on d7 p.i.
 
Although a decrease was 
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seen between d5 p.i. and d7 p.i., it was not significant (Figure 4.2, E). This showed 
that degeneration of RGCs started before the onset of clinical symptoms. 
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Figure 4.2 Number of Fluorogold-labelled RGCs was reduced from d5 p.i. onwards (data and 
pictures provided by Dr. Richard Fairless) 
Representative images were taken from sham-immunised animals (A), d7 p.i. (B), d1 of EAE (C) and 
d8 of EAE (D).Numbers of RGCs in sham-immunised animals were similar to those of healthy animals. 
Cell counts showed a significant decrease in the numbers of RGCs from d5 p.i. onwards when 
compared to retinas of sham-immunised animals (E). (* = p ≤ 0. 05, ** = p ≤ 0. 01. ** = significant to 
healthy, *, ** =significant to sham, n = 4 for all timepoints). Scale bar = 50 µm.  
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4.3 Onset of optic neuritis did not correlate with onset of RGC 
degeneration 
Since the clinical score is only a correlate of spinal cord lesion load, the time course 
of optic neuritis was examined to assess how it correlates with the early degeneration 
of RGCs seen in Figure 4.2. Demyelination, infiltration with inflammatory cells and 
axonal pathology in the optic nerve were examined. 
 
4.3.1 No demyelination could be observed in the induction phase 
To assess how early in the disease course demyelination starts, longitudinal- and 
cross-sections of ONs were stained with Luxol Fast Blue (LFB). LFB binds to the 
hydrophobic myelin protein and produces a blue colour in myelinated areas, whereas 
Schiff´s reagent stains cytoplasm and connective tissue pink. In healthy and sham-
immunised animals and on d5 p.i., d7 p.i. and d10 p.i., the ON is fully myelinated 
(Figure 4.3 A, B, E and F). By d1 of EAE, there was a significant increase in 
demyelinated area (57.57 ± 6.35 %, Figure 4.3 C, G, I) and by d8 of EAE the ONs 
were nearly completely demyelinated (98.84 ± 0.41 %, Figure 4.3, D, H, I). In addition 
the whole area of the optic nerve was measured to look for optic nerve swelling. 
There was significant swelling on d5, d7 and d10 p.i. when compared to healthy but  
swelling was also observed in sham-immunised animals and is therefore likely to be 
a byproduct of the immunisation and since no degeneration of RGCs could be 
observed in sham-immunised animals not involved in degeneration. On d1 and d8 of 
EAE profound optic nerve swelling could be observed (Figure 4.4) when compared to 
both healthy and sham-immunised animals. 
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Figure 4.3 Myelin specific staining (LFB) during the disease course shows that demyelination 
starts at d1 of EAE 
Demyelination was examined with LFB staining of ON cross and longitudinal sections. Representative 
images were taken from sham-immunised animals (A, E), d10 p.i. (B, F), d1 of EAE (C, G) and d8 of 
EAE (D, H). Demyelination started on d1 of EAE at d8 of EAE the nerves were nearly completely 
demyelinated. Asterisks indicate demyelinated areas. (I) shows the percentage of demyelination in ON 
cross-sections. (** = p ≤ 0. 01. ** = significant to healthy, ** = significant to sham, n = 3 for all 
timepoints). Scale bar = 100 µm 
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Figure 4.4 Area of the optic nerve measured from cross-sections  
The area of the optic nerve was measured from cross-sections. It was significantly increased in sham-
immunised animals and during the induction phase and also on d1 and 8 of EAE when compared to 
both healthy and sham-immunised animals. (** = p ≤ 0. 01. ** = significant to healthy, ** = significant to 
sham, n = 3 for all timepoints).  
 
4.3.2 No axonal loss could be observed during the induction phase 
To assess if the numbers of axons within the ON during the course of optic neuritis 
are reduced, cross-sections were stained with Bielschowsky´s silver impregnation. 
On d5, d7 and d10 p.i, the numbers of axons were similar to the ones in healthy and 
sham-immunised animals (Figure 4.5, A, B). The number of surviving axons was 
reduced on d1 of EAE and to a greater extent on d8 of EAE (Figure 4.5, C and D). 
The percentage of surviving axons decreased significantly (**p ≤ 0, 01) from healthy 
and sham-immunised animals to d1 of EAE and to d8 of EAE (Figure 4.5, E). To 
examine if subtle axonal injury occurs in the induction phase the concentration of tau 
in the CSF was measured. Elevated tau concentration in the CSF can for example be 
observed in patients with TBI and is considered a potential marker for clinical 
outcome (Zemlan et al., 1999; Zemlan et al., 2001; Ost et al., 2006). Most studies 
show elevated tau concentration in MS patients even though this finding is not 
unanimous (reviewed by Tumani et al., 2008). For this a multi-spot ELISA was used. 
No increase in tau concentration could be observed during the induction phase but 
tau concentration was significantly increased on d1 and d8 of EAE when compared 
to healthy and sham-immunised animals (Figure 4.6), correlating with the data 
obtained with Bielschowsky´s silver impregnation. 
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Figure 4.5 Bielschowsky´s silver impregnation showed reduced number of axons on d1 and d8 
of EAE 
Axonal loss was examined using Bielschowsky´s silver impregnation on ON cross-sections. 
Representative images were taken from sham-immunised animals (A), d10 p.i. (B), d1 of EAE (C) and 
d8 of EAE (D). On d1 of EAE the number of axons was significantly reduced and on d8 of EAE only a 
few axons remained. Arrows indicate axons (black) and macrophages (blue). (E) Quantification of the 
number of surviving axons. (** = p ≤ 0. 01. ** =significant to healthy, ** =significant to sham, n = 3 for 
all timepoints). Scale bar = 25 µm  
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Figure 4.6 Concentration of tau in the CSF was elevated on d1 and d8 of EAE 
Tau concentration was significantly elevated on d1 and d8 of EAE when compared to healthy and 
sham controls. (* = p ≤ 0.05, ** = p ≤ 0.01. ** = significant to healthy, *, ** = significant to to sham, n = 5 
for d7 p.i, n = 6 for sham, d10 p.i., d1 and d8 of EAE, n = 7 for d5 p.i. and n = 9 for healthy) 
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4.3.3 No infiltration with CD3 positive cells could be observed in the 
induction phase 
T-cells are considered to play a fundamental role in immunopathogenesis in EAE. 
Autoreactive T-cells (against myelin proteins such as MBP) cause EAE symptoms in 
healthy recipient animals, emphasizing their importance in disease induction (Ben-
Nun et al., 1981). Sham-immunised animals do not develop clinical symptoms, 
confirming that MOG-specifity of the T-cell-mediated disease induction. To asses 
how early during the disease course infiltration with T-cells in the optic nerve starts, 
an antibody against CD3 was used. Clusters of differentiation (CD) are cell surface 
molecules which can be used to distinguish different types of immune cells since they 
have unique expression patterns. In addition to CD45 which is expressed by all types 
of leucocytes, T-cells express the CD3 antigen. Only occasionally CD3-positive cells 
could be found in healthy and sham-immunised animals and before the onset of EAE 
(Figure 4.7 A and B). On d1 and d8 of EAE the number of CD3 positive cells was 
elevated (Figure 4.7 C and D). The number increased significantly (*p ≤ 0.05) from 
1.11 ± 0.54 cells / mm2 in healthy and 1.11 ± 0.41 cells / mm2 in sham-immunised 
animals to 170.13 ± 66.45 cells / mm2 on d1 of EAE and 121.71 ± 27.89 cells / mm2 
on d8 of EAE (Fig 3.7 E).  
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Figure 4.7 Number of CD3 positive cells was increased on d1 and d8 of EAE 
The number of T-cells was examined using an antibody against CD3 on ON cross-sections. 
Representative images were taken from sham-immunised animals (A), d10 p.i. (B), d1 of EAE (C) and 
d8 of EAE (D). In the induction phase only occasional CD3 positive cells could be seen (A, B). Their 
number increased significantly on d1 and d8 of EAE (C, D). Arrows indicate CD3 positive cells. (E) 
Quantification of CD3 positive cells / mm2 (** = p ≤ 0. 01. ** = significant to healthy, ** = significant to 
sham, n = 3 for healthy, sham, d10 p.i. and d1 of EAE, n = 4 for d5 p.i., d7 p.i. and d8 of EAE). Scale 
bar = 50 µm 
 
The fact that RGC degeneration in our model started before the onset of optic 
neuritis is of particular interest considering recent publications suggesting the 
possibility of primary retinal pathology where patients not affected by optic neuritis 
show signs of retinal pathology such as macular thinning and loss of RGCs 
(Syc et al., 2011; Saidha et al., 2011). 
 
4.4 Increase in number of ED1 positive cells in the optic nerve started 
during the induction phase 
Besides T-cells, microglia/macrophages are a main part of the inflammatory 
response and their numbers correlate with axonal loss in acute lesions (Ferguson et 
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al.,1997; Trapp et al., 1998). They can secrete pro-inflammatory cytokines and toxic 
mediators thus contributing to axonal loss during optic neuritis. The ED1 antigen can 
be found on activated microglia and macrophages. On d5 p.i., d7 p.i. and d10 p.i, 
ED1 positive cells displayed a microglia-like phenotype (Figure 4.8, B), with long thin 
processes (del Rio Hortega, 1932) and only weak staining around the cell-body. After 
the onset of EAE a robust increase in cells numbers could be seen and the ED1 
positive displayed strong staining of the whole cell membrane and a foamy shape 
similar to that described for macrophages (del Rio Hortega, 1932) (Figure 4.8; C and 
D). These results were confirmed with an antibody against the proinflammatory 
cytokine EMAP II, which is expressed by activated microglia and macrophages. 
Staining with this antibody showed similar results, with increased numbers of 
microglia-like shaped cells (Figure 4.8, E) during the induction phase and 
macrophage-like cells after the onset of EAE (Figure 4.8, F).The number of ED1 
positive cells amounted 6.00 ± 1.35 cells / mm2 in healthy animals and increased to 
12.44 ± 1.66 cells/mm2 on d5 p.i, 29.33 ± 2.31 cells / mm2 on d7 p.i, 
15.83 ± 2.78 cells / mm2 on d10 p.i, 437.95 ± 52.66 cells / mm2 on d1 of EAE and 
427.43 ± 31.03 cells / mm2 on d8 of EAE. There was a significant (**p ≤ 0.01) 
increase at these timepoints when compared to healthy animals and corresponding 
sham-controls. 
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Figure 4.8 Number of ED1 positive cells was increased from d5 p.i. onwards 
The number of microglia/macrophages was examined using an antibody against ED1 on ON 
longitudinal sections. Representative images were taken from sham-immunised animals (A), d5 p.i. 
(B), d1 of EAE (C) and d8 of EAE (D). The results were confirmed with immunohistochemistry with 
EMAP II, another antibody against activated microglia/macrophages (E, F). In the induction phase the 
ED1 and EMAP II positive cells showed a microglia-like appearance with long, thin processes (B, E). 
After the onset of clinical symptoms they looked like macrophages, with stronger expression of 
ED1/EMAP II and a foamy appearance (C, D, and F). The number of ED1 positive cells was increased 
significantly from day 5 p.i. onwards when compared to healthy animals and corresponding sham 
controls. Arrows indicate microglia-like cells (black) and macrophage-like cells (red). (G) Quantification 
of ED1 positive cells / mm2 (** = p ≤ 0. 01. ** = significant to healthy, ** = significant to corresponding 
sham control, n = 3 for shams, n = 4 for d7 p.i., d10 p.i., d1 and d8 of of EAE, n = 5 for healthy and d5 
p.i. and n = 6 for d3 p.i.). Scale bar = 50 µm. 
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4.5 Proliferation of microglia and macrophage-like ED1 positive cells 
started during the induction phase 
In order to assess if the microglia and macrophage-like cells which can be seen 
during the course of EAE are proliferating, an antibody against the Proliferating Cell 
Nuclear Antigen (PCNA), which can be found in the nuclei of cells during the DNA 
synthesis phase of the cell cycle, was used in combination with ED1. For 
immunohistochemistry it was decided to use SG as a substrate for PCNA and DAB 
as a substrate for ED1 because PCNA positive and negative cells are easier to 
distinguish when stained with SG.  
Longitudinal sections of ONs were then double stained with antibodies against PCNA 
and ED1. ED1+ cells and ED1+ + PCNA+ cells were counted. The total number of 
ED1+ cells was increased from d5 p.i. onwards, as was already shown in Figure 4.8, 
G. The percentage of ED1 and PCNA+ positive cells was significantly increased from 
healthy (38.77 ± 7.19 %) to d5 p.i (62.95 ± 6.14 %), d7 p.i (58.77 ± 6.71 %) and d1 of 
EAE (60.45 ± 2.80 %). When compared to sham-immunised animals the number of 
proliferating cells was increased on d5 p.i. and d1 of EAE, demonstrating that ED1 
positive cells proliferate in the induction and clinical phases of EAE. 
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Figure 4.9 Proliferation of ED1 positive cells started during the induction phase  
Representative images were taken at d7 p.i (A) and d1 of EAE (B). Red arrows indicate ED1 and 
PCNA positive cells, blue arrows indicate PCNA positive cells and green arrows indicate ED1 positive 
cells. (C) Percentage of ED1 and PCNA positive cells / mm2 (* = p ≤ 0.05, ** = p ≤ 0.01, *, ** = 
significant to healthy, *,** = significant to to sham, n = 3 for sham, d5 p.i., d10 p.i and d1 of EAE, n = 4 
for d7 p.i. and n = 5 for healthy). Scale bar = 50 µm  
 
4.6 Animals can develop optic neuritis independently from clinical 
symptoms 
The following part addresses the possibily that the development of optic neuritis is a 
distinct process to the formation of spinal cord lesions and thus clinical symptoms. 
62.5% of immunised animals developed EAE (Figure 4.11), but for the remaining 
37.5% which did not develop clinical signs of EAE, it was decided to investigate their 
optic nerves for pathological signs of optic neuritis. Eight animals which did not 
develop clinical EAE symptoms by d30 p.i. were sacrificed. The ONs of four animals 
were made into longitudinal sections, the ONs from the other four into cross sections. 
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Cross-sections were stained with LFB and Bielschowsky and antibodies against ED1 
and CD3 were used on longitudinal sections. The ONs could be divided into two 
groups: One group showed no demyelination and no reduction in numbers of axons 
when compared to sham-immunised animals (Figure 4.10, A, B, I and J, blue 
columns). The other group showed substantial demyelination and reduced number of 
axons. The demyelination and loss of axons in this group was significantly increased 
(**p≤ 0. 01) when compared to sham-immunised animals and demyelination and 
axonal loss was also significantly higher than on d1 of EAE (Figure 4.10, E, F, I and 
J, red columns).  
In addition, immunohistochemistry against ED1 and CD3 was performed on the 
longitudinal sections. The group with no demyelination shows a significant increase 
in infiltrating CD3-positive cells (Figure 4.10, C and K) but numbers are smaller than 
at d1 of EAE. There is also a significant increase in ED1 positive cells which show a 
microglia-like shape (Figure 4.10 D and L, blue column). 
The group with demyelination showed robust infiltration of CD3 positive cells (Figure 
4.10, G and K, red column) and macrophage-like ED1 positive cells (Figure 4.10, H). 
The number of ED1 positive cells was significantly (**p≤ 0. 01) elevated compared to 
sham-immunised animals and d10 p.i. (Figure 4.10, L, red column).  
This shows that optic neuritis can be developed independently from clinical 
symptoms and that demyelination is highly correlated with the presence of infiltrating 
cells.  
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Figure 4.10 Some animals without clinical symptoms of EAE still developed optic neuritis  
Representative images of two optic nerves from animals with no clinical symptoms (A-D and E-H) 
Representative images from an ON with no signs of optic neuritis (A-D). Nerve showed no 
demyelination (A), no change in axonal density (B), some CD3 positive cells (C) and ED1 positive 
cells with a microglia-like shape (D). Representative images from an optic nerve with optic neuritis (E-
H). The ON was demyelinated (E), the number of axons was reduced (F), many CD3 positive cells 
could be seen (G) and ED1 positive cells showed a macrophage-like shape (H). Arrows indicate axons 
(red), CD3 positive cells (black) and ED1 positive cells (blue).The extent of demyelination and axonal 
loss was significantly higher than on d1 of EAE (I, J). The number of CD3 positive and ED1 positive 
cells was elevated in the group without demyelination and was strongly elevated in nerves showing 
demyelination and axonal loss, again comparable to d1 of EAE (K, L) (** = p ≤ 0.01, ** = significant to 
sham, ** = significant to d1 of EAE, n = 3 for sham, d10 p.i and d1 of EAE, n = 4 for animals without 
symptoms). Scale bar = 100 µm A, C, D, F and 50 µm B, E.  
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Figure 4.11 The incidence of optic neuritis was much higher than the incidence of clinical 
symptoms  
62.5% of the immunised animals developed EAE and in this group only one ON showed no signs of 
optic neuritis. In the group without symptoms 53% of the examined ONs showed demyelination. The 
overall incidence of optic neuritis is 78.4% and thus higher than the incidence of EAE.  
 
In summary 53% of the ONs of animals without clinical symptoms show extensive 
demyelination (Figure Figure 4.11) and also axonal loss and 50% of the longitudinal 
ON sections show elevated numbers of CD3 positive and ED1 positive cells with a 
macrophage-like morphology, all hallmarks of optic neuritis. The incidence of optic 
neuritis is therefore higher (78.4%) than the incidence of clinical symptoms (62.5%). 
It is possible that the optic nerve is more vulnerable due to smaller diameter and it is 
known that MOG expression is higher in the optic nerve than the spinal cord 
(Betelli et al., 2003). 
 
4.7 Anti-MOG antibodies were increased during the induction phase 
The role of antibodies against myelin proteins in pathogenesis in MS has been 
studied extensively but studies show conflicting results as to their usefulness in 
predicting relapses of MS and their overall involvement in pathogenesis. 
Immunisation with MOG, a protein located on the surface of the myelin sheath, 
induces EAE in a variety of species usually accompanied by only a low grade of 
    
62 Results 
demyelination (Gold et al., 2006). Brown Norway rats are particularly susceptible to 
antibody-mediated diseases and immunisation with MOG causes a severe 
demyelinating autoantibody response. In order to determine if anti-MOG antibodies 
could be involved in the previously observed early degeneration of RGCs (Figure 
4.2), serum samples from different timepoints after immunisation and onset of clinical 
symptoms were compared to serum from healthy and sham-immunised animals, 
using the ELISA technique. The antibody titre was significantly elevated from d10 p.i 
onwards (Figure 4.12), preceding the onset of clinical symptoms but started several 
days after onset of RGC degeneration, suggesting that anti-MOG antibodies are not 
involved in early degeneration of RGCs. 
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Figure 4.12 The concentration of MOG antibody was elevated from d10 p.i. onwards 
The MOG antibody concentration was significantly elevated from d10 p.i onwards when compared to 
healthy and sham controls. (* = p ≤ 0. 05. * = significant to healthy, * = significant to sham, n = 4 for all 
timepoints).  
 
4.8 Increased number of ED1 positive cells in the retina correlated with 
onset of RGC degeneration  
An increase in the number of ED1 positive cells was observed in the optic nerve 
during the induction phase and microglia/macrophages could be involved in the early 
loss of RGCs, therefore their presence in the retina was examined. The number of 
ED1 positive cells was increased significantly from d5 p.i onwards during the 
induction phase (Figure 4.13, C). In healthy animals the number of cells was 
2.3 ± 0.11 cells / mm. On d5 p.i., d7 p.i. and d10 p.i the number of cells was 
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4.6 ± 0.23 cells / mm, 3.38 ± 0.21 cells / mm and 3.43 ± 0.26 cells / mm, which was 
significantly (**p ≤ 0.01) higher than in healthy animals and corresponding sham 
controls (**p ≤ 0.01 and *p ≤ 0.05). There was no significant increase in sham-
controlls when compared to healthy animals.After the onset of EAE the number of 
ED1 positive cells was reduced to 2.27 ± 0.22 cells / mm on d1 of EAE which was 
only significantly higher compared to the corresponding sham control. The ED1 
positive cells showed a microglia-like shape during the disease course (Figure 4.13 A 
and B). 
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Figure 4.13 Number of ED1 positive cells in retinal ganglion cell layer was increased from d5 
p.i. onwards  
ED1 positive cells show a microglia-like morphology in the induction phase (A) and also after onset of 
EAE (B). The increase in ED1 positive cells was significant in the induction phase of the disease when 
compared to healthy animals and corresponding sham controls. After the onset of EAE the number of 
ED1 positive cells was reduced (C). (* = p ≤ 0. 05, ** = p ≤ 0. 01. ** = significant to healthy, 
*
, 
** = significant to corresponding sham, n = 3 for shams, d3 p.i., d5 p.i., d10 p.i and d1 of EAE, n = 4 
for d7 p.i.). Scale bar = 50 µm.  
    
64 Results 
 
4.9 Increased GFAP expression in the retina correlated with microglial 
activation and onset of RGC degeneration 
In addition to microglia, the retina contains two types of macroglial cells: Müller cells 
and astrocytes. Astrocytes are located in the ganglion cell layer and nerve fibre layer 
and express the glial fibrillary acidic protein (GFAP). Müller cells are located in the 
inner nuclear layer (cell body) with processes projecting to the inner and outer 
plexiform layer (Reichenbach et al., 1989) and only express detectable levels of 
GFAP after retinal insults (Bignami and Dahl, 1979; Björklund and Dahl, 1985). 
Astrocytes become reactive after various insults, and can be identified by elevated 
expression of GFAP and thicker processes (hypertrophy) (Latov et al., 1979; Brock 
and O'Callaghan, 1987; Eng et al, 2000). Activation of microglia/macrophages and 
astrocytosis are often found in parallel after insults to CNS tissue with cytokine 
signalling providing a mean of communication between these cell types during 
inflammation (Dong and Benveniste, 2001). In order to assess if the activation of 
microglia is accompanied by increased reactivity in aystrocytes and Müller cells, 
immunohistochemistry with an antibody against GFAP was performed. This revealed 
increased expression in the ganglion cell layer and also GFAP-positive processes in 
the inner plexiform layer from d5 p.i. onwards, when compared to healthy and sham-
immunised animals (Figure 4.14 A, B and C), suggesting increased activation of 
astrocytes and probably Müller cells. Western blots with retina lysates were 
performed to quantify the changes in GFAP expression. A significant increase in 
GFAP expression could be seen from d5 p.i. onwards when compared to healthy and 
sham-immunised animals (Figure 4.14, D and E). These results suggest that reactive 
gliosis in the retina started on d5 p.i., correlating with microglial activation and onset 
of RGC degeneration. 
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Figure 4.14 GFAP expression in the retina was upregulated from day 5 p.i. onwards 
Representative images were taken from sham-immunised animals (A), d5 p.i (B) and d1 EAE (C). 
Increased GFAP expression could be seen from d5 p.i onwards, which was confirmed with western 
blot analysis (D, E) (* = p ≤ 0. 05, ** = p ≤ 0. 01. *, ** = significant to healthy, *, ** = significant to sham, 
n = 4 for d8 of EAE, n = 5 for d3 p.i., d5 p.i. and d1 of EAE, n = 6 for healthy and d10 p.i. and n = 7 for 
sham and d7 p.i.). Scale bar = 50 µm.  
 
4.10 Cytokine concentrations were not elevated during the induction 
phase 
Concentrations of several cytokines are elevated in the CSF of MS patients, for 
example it has been proposed that the chemokine CXCL13 can be used to predict 
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conversion from CIS to MS (Brettschneider et al., 2010). Cytokines have also been 
implied in the early activation of microglia (Marik et al., 2007). With the multispot 
assay technique the concentration of several cytokines in the CSF was measured. 
There was no detectable change in concentration of Il-4, IL-5, IL-13, IL-1β, IFN-γ and 
TNF-α during the induction phase and after onset of clinical symptoms. The 
concentration of GRO (CXCL1) increased significantly (*p ≤ 0.01) on d1 of EAE 
(Figure 4.15). CXCL1 is a chemokine that is released by reactive astrocytes and 
binds to the CXCR2 receptor which is expressed on neutrophils and responsible for 
their chemotactic response (Bozic et al., 1995; Van Damme et al., 1997), thus 
promoting inflammation. 
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Figure 4.15 Concentration of CXCL1 in the cerebrospinal fluid is elevated at d1 of EAE 
The CXCL1 concentration was significantly elevated at d1 of EAE when compared to healthy and 
sham controls. (** = p ≤ 0. 01. ** = significant to healthy, ** = significant to sham, n = 3 for d3 p.i., d7 
p.i.and d10 p.i., n = 4 for sham, d1 and d8 of EAE, n = 6 for d5 p.i. and n = 7 for healthy).  
 
4.11 Manganese enhancement in the retina and optic nerve started 
during the induction phase 
To address the timing of calcium influx during the disease course of EAE, 
manganese-enhanced MRI (MEMRI) was performed, using manganese chloride 
(MnCl2) as a contrast agent in T1-weighted MRI. Manganese ions (Mn2+) are able to 
enter cells via the same entry pathways as calcium ions, such as voltage-dependent 
calcium channels (VDCCs) (Lin and Koretsky; 1997; Takeda, 2002) and ionotropic 
glutamate receptors, and therefore manganese-enhanced MRI can be used to 
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monitor calcium influx in the retina and the optic nerve. In addition MRI was used to 
monitor anatomical changes in the optic nerve. 
 
4.11.1 Optic nerve swelling could be seen in the induction phase and 
after onset of optic neuritis 
T2-weighted RARE scans were used to measure changes in the width of the optic 
nerve during the disease course. There was a significant increase in sham-
immunised animals and d10 p.i. when compared to healthy animals (Figure 4.16, D) 
and no difference between sham-immunised animals and d10 p.i. (Figure 4.16, A, B 
and D). At d1 of EAE there was a significant increase compared to both healthy and 
sham-immunised animals (Figure 4.16, C and D). This agrees with the results from 
measuring the area of the optic nerve (Figure 4.4) showing that the previously 
observed results from the histophathological staining are not caused by artefacts due 
to the fixation process. 
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Figure 4.16 Width of the optic nerve is increased on d1 of EAE 
Representative images of T2-weighted scans were taken from sham-immunised animals (A), d10 p.i 
(B) and d1 of EAE (C). Arrows indicate the brain (blue), optic nerves (red) and optic chiasm (green). 
The yellow line indicates where the width was measured. There is a significant increase in the width of 
the optic nerve in sham-controls and d10 p.i when compared to healthy animals but no difference 
between d10 p.i. and sham control. There is a significant increase in width on d1 of EAE when 
compared to both healthy and sham. (D) Measurement of optic nerve width. (* = p ≤ 0.05, ** = p ≤ 
0.01. *, ** = significant to healthy, ** = significant to sham, n = 4 for sham, n = 5 for d1 of EAE, n = 6 for 
healthy and n = 9 for d10 p.i.). Scale bar = 1 mm.  
 
4.11.2 Manganese enhancement in the optic nerve could be seen from 
d10 p.i. onwards 
After positioning with T2-weighted RARE scans, 3D FLASH scans were performed. 
To find the timepoint were the signal enhancement is most prominent, three sick 
animals (d1 EAE) were injected with MnCl2 and signal intensity was measured before 
injection (Figure 4.17, A), 10 minutes after injection (Figure 4.17, B), one hour (Figure 
4.17, C) and two hours (Figure 4.17, D) after injection. In two animals intensity was 
also measured 24 hours after injection.  
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The signal enhancement was slightly stronger 10 minutes after injection when 
compared to the one hour timepoint and stayed stable between one and two hours 
after injection. 24 hours after injection there was still small but significant increase in 
signal intensity (Figure 4.17, E). Since the signal enhancement was strongest 10 
minutes after injection, this timepoint was choosen for further measurements. 
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Figure 4.17 Time course of signal enhancement after MnCl2 injection at d1 of EAE 
Representative images of T1-weighted scans show the baseline value before injection (A), and the 
same nerve 10 minutes, one hour and two hours after MnCl2 injection (B),(C) and (D). The signal 
intensity was increased significantly 10 minutes after injection when compared to the baseline value. 
One hour after injection the signal intensity was slightly reduced and stayed stable between one and 
two hours. At 24 hours the signal intensity was greatly reduced but still significantly elevated (E). 
Arrows indicate the brain (blue) and optic nerves (red). The yellow rectangles and ellipses indicate the 
area measured for signal intensity. (** = p ≤ 0.01, n = 2 for the 24 hour scan, n = 5 for other 
timepoints). Scale bar = 2 mm.  
 
To examine the time course of manganese enhancement, signal intensity was 
measured in healthy and sham-immunised animals, on d7 and d10 p.i and on d1 of 
EAE before MnCl2 injection (Figure 4.18, A, B and C) and 10 minutes after injection 
(Figure 4.18, D, E and F). There was no difference between healthy (signal intensity 
0.99 ± 0.02), sham-immunised animals (signal intensity 0.90 ± 0.05) and on d7 p.i. 
(signal intensity 0.99 ± 0.02). There was a significant increase in manganese 
enhancement on d10 p.i. (signal intensity 1.11 ± 0.05) and on d1 of EAE (signal 
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intensity 1.70 ± 0.08) when compared to sham-immunised and healthy animals 
(Figure 4.18, G).  
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Figure 4.18 Manganese enhancement in the optic nerve during the course of optic neuritis.  
Representative images of T1-weighted scans show the baseline value before MnCl2 injection in sham-
immunised animals (A), d10 p.i (B) and d1 of EAE (C) and the same nerve 10 minutes after injection 
(D-F). Arrows indicate the brain (blue) and optic nerves (red). The yellow rectangles and ellipses 
indicate the area measured for signal intensity. No change in signal enhancement could be seen on 
d7 p.i when compared to healthy and sham-immunised animals. There was a significant increase on 
d10 p.i and d1 EAE. (* = p ≤ 0.05, ** = p ≤ 0.01, *, ** = significant to healthy, ** = significant to sham, 
n = 3 for healthy and d7 p.i., n = 4 for sham, n = 5 for d1 of EAE and n = 6 for d10 p.i.). Scale bar = 
2 mm.  
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4.11.3 Manganese enhancement in the retina could be seen from d5 p.i. 
onwards 
After positioning with T2-weighted RARE scans, MSME scans were performed 
before and after injection of MnCl2. To find the timepoint after injection where the 
signal enhancement is most prominent, animals at d5 p.i were injected with MnCl2 
and signal intensity was measured before injection (Figure 4.19, C), 10 minutes after 
injection (Figure 4.19, D), one hour (Figure 4.19, E) and two hours (Figure 4.19, F) 
after injection. Signal intensity was increased significantly 10 minutes after injection 
and reached its peak one hour after injection (Figure 4.19, G) and this timepoint was 
used for further experiments. 
To examine the time course of manganese enhancement, signal intensity was 
measured in healthy and sham-immunised animals, on d3 p.i, d5 p.i., d10 p.i. and on 
d1 of EAE before MnCl2 injection and one hour after injection. 
Signal intensity after MnCl2 injection in healthy, sham-immunised animals and at d3 
p.i. was very similar (Figure 4.20, G). From d5 p.i. onwards MnCl2 injection caused a 
profound increase in signal enhancement (Figure 4.20, B-F) and signal intensity was 
significantly increased when compared to healthy and sham-immunised animals 
(Figure 4.20, G). The fact that manganese enhancement can be seen from d5 p.i. 
onwards, correlating with onset of RGC degeneration suggest that calcium influx 
might play a role in the death of RGCs at this timepoint. 
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Figure 4.19 Signal enhancement in the retina is highest one hour after MnCl2 injection  
Representative image of a T1-weighted scan at d5 p.i. shows which areas of the retina and brains 
were measured (A and B). The yellow ellipses indicate the brain area measured as control for signal 
intensity and the green are indicates the area of the retina that was measured. 
Signal intensity was measured before MnCl2 injection (C), 10 minutes after injection (D), one hour after 
injection (E) and two hours after injection (F). The same images are shown as false colour images (G-
J). The signal intensity was significantly increased 10 minutes after injection and highest one hour 
after injection. (K) Measurement of signal intensity (** = p ≤ 0.01. ** = significant to before injection, 
** = significant to 10 minutes after injection, n = 4 for the 10 minutes scan, n = 5 for one and two hour 
scans) Scale bar = 2 mm in A and 1 mm in C-J.  
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Figure 4.20 Manganese enhancement in the retina started during the induction phase 
Representative images of T1-weighted scans show the baseline value before MnCl2 injection in sham-
immunised animals (A), d5 p.i (B) and d1 EAE (C) and one hour after MnCl2 injection (D, E, F). There 
was a significant increase on d5 p.i., d10 p.i. and d1 of EAE when compared to healthy and sham-
immunised animals (G).Since the baseline value before injection was set to one, the scale was also 
set to one as a minimum value. (* = p ≤ 0.05. * = significant to healthy, * = significant to sham, n = 4 
for healthy, sham, d3 p.i., d10 p.i. and d1 of EAE, n = 5 for d5 p.i.) Scale bar = 1 mm).  
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4.11.4 Treatment with the NMDA receptor blocker MK 801 reduced 
manganese enhancement in the retina 
The NMDA receptor (ionotropic glutamate receptor) has been shown to play an 
important role in retinal degeneration. Blockade of the receptor with the antagonist 
MK-801 reduces death of cultured RGCs after glutamate exposure (Pang et al., 
2007) and also reduces calcium influx in cultured RGCs (Hartwick et al., 2008). In the 
following experiments the role of the NMDA receptor in the previously observed 
manganese enhancement was examined. Animals were taken at d5 p.i. because 
there was strong signal enhancement at this timepoint (Figure 4.20, G) and the early 
manganese enhancement correlates with onset of RGC degeneration.  
Signal intensity was measured in healthy animals and at d5 p.i before and one hour 
after MnCl2 injection. Animals were injected with MK801 40 minutes prior to MnCl2 
injection; the control group received a saline injection. At d5 p.i. there was a 
significant increase in signal enhancement in the control group when compared to 
the healthy control group (Figure 4.21, A, B and E), as was already shown in 
untreated animals. In the animals treated with MK801 a significant reduction in signal 
intensity could be seen at d5 p.i (Figure 4.21 B, D, and F) suggesting that influx 
through NMDA receptors contributes to manganese enhancement. 
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Figure 4.21 Treatment with the NMDA receptor blocker MK801 significantly reduced 
manganese enhancement at d5 p.i 
Representative images of T1-weighted scans show a retina at d5 p.i. before MnCl2 injection with saline 
injection (A) and one hour after MnCl2 injection (B) and at d5 p.i. with injection of MK 801 (C) and one 
hour after injection of MnCl2 (D). The injection of MnCl2 caused a significant increase in signal intensity 
at d5 p.i. when compared to healthy animals (E) and signal intensity was decreased significantly at d5 
p.i. in animals that received MK801 but not in healthy animals (E). (* = p ≤ 0.05, n = 4 for healthy and 
d5 p.i. with saline and d5 p.i. with MK801, n = 6 for healthy with MK801). Scale bar = 1 mm.  
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4.12 Increased amount of BDPN in the retina and optic nerve could be 
observed during the induction phase  
The loss of RGCs can be seen very early in the disease course. A mechanism 
implicated in pathology in both acute neurodegenerative disorders and chronic 
neurodegenerative diseases is an increase in calpain activity as a result of calcium 
dysregulation (Vosler et al., 2008). A commonly used method for measuring 
increased calpain activity is using an antibody against spectrin breakdown products 
(SBDPs). Spectrin is a cytoskeletal protein which can be cleaved into different 
SBDPs by caspase 3 and calpain. Calpain cleavage leads to breakdown products 
with a size of 145 kDa and 150 kDa. Caspase 3 cleavage produces breakdown 
products with a size of 120 kDa and 150 kDa. An antibody that recognizes all the 
breakdown products was used first but since the breakdown products are difficult to 
distinguish due to their similar sizes, an antibody specific for one of the calpain 
cleaved breakdown products was later used (BDPN against the 145 kDa breakdown 
product).  
4.12.1 Elevated concentration of BDPN in the optic nerve correlated with 
manganese enhancement 
With the antibody against all breakdown products two bands of approximatley 
150 kDa in size could be seen. Due to the very similar size (Figure 4.22) it was 
impossible to quantify these bands. Therefore the antibody against BDPN was used 
to quantify changes in the amount of spectrin breakdown product and thus calpain 
activity. 
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Figure 4.22 An antibody against caspase-3 and calpain cleaved spectrin produced bands to 
similar in size to be quantified 
Initially an antibody was used that recognizes spectrin breakdown products produced by calpain and 
caspase-3 cleavage. Since the cleavage products are very similar in size (145 kDa for calpain and 150 
kDa for caspase-3, indicated with red arrows), quantification was not possible. For further experiments 
an antibody that only recognises one of calpain-mediated spectrin breakdown products was used. 
 
As expected, with the antibody specific against BDPN, 145 kDa only one band can be 
seen in the western blot (Figure 4.23 , A). The relative level of BDPN is elevated in 
sham-immunised animals and on d3 p.i., d5 p.i. and d7 p.i. when compared to 
healthy animals and significantly elevated from d10 p.i. onwards when compared to 
sham-immunised animals (Figure 4.23, B). This correlates well with the results from 
manganese enhanced MRI where enhancement could be seen at d10 p.i. and d1 of 
EAE. In the optic nerve no axonal loss can be seen at d10 p.i.; the activation of 
calpain might therefore correlate with subtle axonal changes prior to axonal loss. 
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Figure 4.23 Calpain-specific spectrin breakdown product (BDPN) in optic nerves was elevated 
from d10 p.i. onwards 
An antibody specific to BDPN showed one band at 145 kDa (A). GAPDH was used as a loading 
control. (B) There was an increase in BDPN in sham-immunised animals and between d3 p.i. and d7 
p.i. when compared to healthy animals and a further significant increase on d10 p.i. when compared to 
both healthy and sham-immunised animals. The increase in BDPN indicates increased calpain activity 
from d10 p.i. onwards. (* = p ≤ 0.05, ** = p ≤ 0.01. *, ** = significant to healthy, *, ** = significant to 
sham, n = 4 for sham, n = 5 for d10 p.i. and d8 of EAE, n = 6 for healthy, d7 p.i. and d1 of EAE, n = 7 
for d3 p.i. and d5 p.i.).  
 
4.12.2 Onset of elevated concentration of BDPN in the retina correlated 
with manganese enhancement and degeneration of RGCs 
For the retinal lysates only the antibody for the calpain-mediated spectrin breakdown 
was used. The relative level of BDPN was significantly elevated on d5 p.i. and d7 p.i., 
when compared to both sham-immunised and healthy animals (Figure 4.24 A, B). 
There was also a slight increase at d10 and d1 of EAE which was only siginificant 
compared to healthy animals.  
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The onset of increased amount of BDPN at d5 p.i. correlated with the result from 
manganese enhanced MRI where increased signal intensity could be seen from d5 
p.i. onwards (Figure 4.20, G) and also correlated with the onset of RGC 
degeneration. 
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Figure 4.24 Calpain-specific spectrin breakdown product in retina was elevated on days 5 and 7 
p.i. 
An antibody specific to the calpain-cleaved spectrin breakdown product showed one band at 147 kDa 
(A). GAPDH was used as a loading control. (B) Relative levels of spectrin breakdown product. The 
increase in spectrin breakdown product indicates an increase in calpain activity on d5 and d7 p.i. (* = p 
≤ 0.05, ** = p ≤ 0.01. *, ** = significant to healthy, ** = significant to sham, n = 4 for d3 p.i, n = 6 for 
d5 p.i., n = 7 for d10 p.i.and d8 of EAE, n = 10 for sham, d7 p.i. and d1 of EAE).  
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4.13 Calpeptin treatment reduced RGC degeneration in the induction and 
clinical phase and reduced symptoms of optic neuritis 
The previous results imply that calpain activity is increased during the induction 
phase of EAE in both the retina and optic nerve. In the retina we see evidence of 
elevated calcium influx (shown by increased signal enhancement in manganese-
enhanced MRI), starting at d5 p.i., correlating with onset of RGC degeneration.  
Increased activity of the calcium-activated protease calpain can also be seen starting 
at d5 p.i. To determine if calpain activity plays a crucial role in early degeneration of 
RGCs, and could therefore be a potential target for neuroprotective therapies, calpain 
activity was inhibited with calpeptin. 
In addition calpain activity has been implicated to play a role in T-cell migration 
(Butler et al., 2009). Calpeptin treatment might therefore also be able to reduce 
inflammatory infiltration and subsequent demyelination and axonal loss after onset of 
optic neuritis. Animals were treated twice daily with an i.p. injection of 250 µg / kg 
calpeptin from the day of immunisation onwards. To confirm that the treatment 
strategy reduced calpain activity, lysates were taken from retinas at d5 p.i. and 
calpain activity was examined with the antibody against calpain-specific spectrin 
breakdown product. There was a trend towards decreased calpain activity after 
calpeptin treatment when compared to untreated animals but it was not significant 
(p=0.055), (Figure 4.25). There was no significant difference in the day of onset of 
clinical symptoms beetween the saline treated (d15.25 ± 0.75 p.i.) and calpeptin 
treated (d16.2 ± 1.24 p.i.) group (Figure 4.26) and also no difference in severity of 
symptoms.  
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Figure 4.25 A trend towards decreased amount of BDPN in retina lysated after calpeptin 
treatment could be observed 
(A) Western blot of retinal lysates at d5 p.i from animals treated with calpeptin and from control 
animals injected with saline. (B) A trend towards decreased amount of calpain-specific spectrin 
breakdown product could be seen, but it was not significant (p = 0.055, n = 7 for both groups).  
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Figure 4.26 No delay in day of onset of clinical symptoms was observed with calpeptin 
treatment 
Animals from the two groupts (calpeptin treated and saline treated) were scored daily for clinical 
symptoms. There was no significant difference in day of onset in the two groups. (n = 4 for saline 
treated and n = 5 for calpeptin treated) 
 
Animals were taken at d1 of EAE for histopathological and immunohistochemical 
staining. Treatment with calpeptin reduced the number of infiltrating CD3 positive 
cells in the optic nerve significantly (Figure 4.27, C) from 114.67 ± 24.61 cells / mm2 
in saline treated animals to 47.9 ± 14.66 cells / mm2 in calpeptin treated animals. 
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The number of ED1 positive cells was also significantly reduced (Figure 4.28, C) from 
988.06 ± 206.6 cells / mm2 in saline treated animals to 206.6 ± 126.476 cells / mm2 in 
calpeptin treated animals.  
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Figure 4.27 Calpeptin treatment reduced the number of CD3 positive cells in the optic nerve at 
d1 of EAE 
The number of T-cells was examined using an antibody against CD3 on ON cross-sections. 
Representative images were taken from a saline treated animal (A) and an animal treated with 
calpeptin (B).The number of CD3 positive cells was significantly decreased in optic nerves of calpeptin 
treated animals (C). (* = p ≤ 0. 05, n = 4 for both groups). Scale bar = 50 µm.  
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Figure 4.28 Calpeptin treatment reduced the number of ED1 positive cells in the optic nerve at 
d1 of EAE 
The number of microglia/macrophages was examined using an antibody against ED1 on ON cross-
sections. Representative images were taken from a saline treated animal (A) and an animal treated 
with calpeptin (B).The number of ED1 positive cells was significantly decreased in optic nerves of 
calpeptin treated animals (C). (* = p ≤ 0. 05, n = 4 for both groups). Scale bar = 50 µm.  
 
 
LFB staining showed that demyelination was significantly decreased after calpeptin 
treatment from 48.35 ± 5.51% in saline treated animals to 13.65 ± 3.65 % in calpeptin 
treated animals (Figure 4.29, A-C). Since Bielschowsky silver impregnation is not a 
very sensitive marker for subtle axonal changes, an antibody against APP was used 
to examine disturbances in axonal transport. There was a significant decrease in 
APP positive axons from 1121.75 ± 187.97 axons / mm2 in saline treated animals to 
580.46 ± 123.75 axons / mm2 in calpeptin treated animals (Figure 4.30, A-C). 
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Figure 4.29 Calpeptin treatment reduced demyelination in the optic nerve at d1 of EAE 
Demyelination was asessed with LFB staining on ON cross-sections. Representative images were 
taken from a saline treated animal (A) and an animal treated with calpeptin (B).The demyelinated area 
was significantly decreased in optic nerves of calpeptin treated animals (C). (** = p ≤ 0. 01, n = 4 for 
both groups). Scale bar = 100 µm.  
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Figure 4.30 Calpeptin treatment reduced number of APP positive cells in the optic nerve at d1 
of EAE 
Disturbed axonal transport was examined using an antibody against APP on ON cross-sections. 
Representative images were taken from a saline treated animal (A) and an animal treated with 
calpeptin (B).The number of APP positive axons was significantly decreased in optic nerves of 
calpeptin treated animals (C). (* = p ≤ 0. 05, n = 4 for both groups). Scale bar = 50 µm.  
 
As mentioned before calpain activity plays an important role in apoptotic cell death 
and reduced calpain activity might contribute to survival of RGCs. Animals were 
sacrificed either on d10 p.i. or d1 of EAE and the number of Fluorogold-labelled 
RGCs in the retina was counted. Treatment with calpeptin increased the number of 
surviving RGCs significantly (*p ≤ 0. 05) at d10 p.i (Figure 4.31, A and B) from 
1021.86 ± 57.17 cells / mm2 in saline treated animals to 1200.25 ± 49.41 cells / mm2 
in calpeptin treated animals (Figure 4.31, E). There was also a significant increase 
(**p ≤ 0. 01) at d1 of EAE (Figure 4.31, C and D) from 726.86 ± 62.37 cells / mm2 in 
saline treated animals to 1045.57 ± 41.77 cells / mm2 in calpeptin treated animals 
(Figure 4.31, E).  
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Figure 4.31 Calpeptin treatment increased the number of surviving RGCs 
Numbers of surviving RGCs were assessed by counting Fluorogold-labelled cells in the retinas from 
animals sacrificed either on d10 p.i. or d1 of EAE. Representative images were taken from saline 
treated animals at d10 p.i. (A) and at d1 of EAE (C) and from calpeptin treated animals at d10 p.i. (B) 
and d1 of EAE (D). Cell counts showed a significant increase in the number of RGCs both at d10 p.i. 
and d1 of EAE in the animals treated with calpeptin. (* = p ≤ 0. 05, ** = p ≤ 0. 01, n = 3 for d1 of EAE 
calpeptin treated, n = 4 for d1 EAE saline treated, n = 6 for d10 p.i. saline treated and n = 8 for d10 p.i. 
calpeptin treated ). 
 
The above result that calpeptin treatment significantly reduces death of RGCs in the 
induction phase, strongly suggests that calcium influx and subsequent calpain 
activation play an important role in early degeneration of RGCs and that calpain 
inhibitiors could be a potential therapy for early neurodegeneration. In addition 
calpeptin treatment sifnificantly reduced inflammatory infiltration after onset of optic 
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neuritis, confirming results in spinal cord of Lewis rats with EAE where treatment with 
calpeptin reduced inflammatory infiltration and demyelination (Guyton et al., 2010), 
suggesting that calpain inhibitors could also be considered as anti-inflammatory 
therapy. 
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5 Discussion 
5.1 RGC death does not only occur secondary to axonal damage 
Death of RGCs is believed to mainly occur secondary to axonal damage of the ON 
during optic neuritis, and is further demonstrated by experiments showing that this 
death shares apoptotic pathways similar to those induced by axotomy (Isenmann et 
al., 1997; (Kermer et al., 1999; Kermer et al., 2000; Meyer et al.; 2001; Hobom et al., 
2004). In our model the number of RGCs is significantly reduced on d5 p.i. (Figure 
4.2) more than a week before the average onset of clinical symptoms (Figure 4.1), 
confirming previous results from our group (Hobom et al., 2004). During the induction 
phase, before onset of clinical symptoms no demyelination, infiltration with T-cells or 
axonal loss was observed in the optic nerve (Figure 4.3, Figure 4.5, Figure 4.7). The 
optic nerve swelling that was observed in the induction phase (Figure 4.4 and Figure 
4.16) is likely to represent a subclinical event with no impact on other parameters as 
is has also been observed in sham-immunised animals where no degeneration of 
RGCs or increased activation of microglia has been observed. 
The timing of optic neuritis, axonal loss and death of RGCs shows that RGCs die 
prior to onset of optic neuritis and even before loss of their axons, thus it appears that 
the degeneration of RGCs is a direct primary event. This result is of special interest 
in the light of recent publications, suggesting the possibility of a primary retinopathy 
in MS patients with no history of optic neuritis (Saidha et al., 2011, Syc et al., 2011). 
 
5.2 Activated microglia in the retina and optic nerve as a potential 
source for excitotoxic glutamate levels 
Microglia reside in the CNS and participate in innate immunity and adaptive immune 
response of the CNS (Garden and Möller, 2006). In the healthy brain, microglia can 
be found in a resting form, with long, thin processes that are moving in order to scan 
the environment (Hanisch and Kettenmann, 2007). Activation of 
microglia/macrophages, which can be identified by the expression of ED1, has been 
described to be a part of numerous insults to the CNS including ischemia, traumatic 
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injury, infections and autoimmune diseases (Kreutzberg, et al., 1996; Gehrmann et 
al., 1995) In our model activated microglia can be found in the retina and optic nerve 
prior to the onset of optic neuritis, correlating with the onset of RGC degeneration. 
After onset of optic neuritis the ED1 positive cells in the optic nerve show a 
macrophage-like shape which is in agreement with studies showing recruitment of 
blood-borne macrophages into the CNS after onset of EAE (Huitinga et al., 1995; 
Polman et al., 1986) as well as morphological changes of intrinsic microglia after 
insult (Kato et al., 2003; Garden and Möller, 2006). In the optic nerve ED1 positive 
cells were found to be proliferating both in the induction phase and after onset of 
clinical symptoms, confirming their activation because activated 
microglia/macrophages express markers for proliferation (Kato et al., 2003) 
Activation of microglia has been suggested as an early event in lesion formation in 
the brain of MS patients. Activated microglia have been observed during 
development of lesions in normal-appearing white matter (NAWM) in MS patients in 
the absence of demyelination (De Groot et al., 2001; van der Valk & Amor, 2009) and 
studies also showed a stage in lesion formation where microglia were activated prior 
to T-cell infiltration and demyelination (Barnett and Prineas, 2004; Gay et al., 1997). 
It was shown that axonal/oligodendrocyte pathology at nodal and paranodal regions 
in the NAWM of MS patients correlates with microglial activation rather than 
infiltration of T-cells and in the spinal cord of mice with MOG-induced EAE microglial 
activation also correlates with disruption of the nodal/paranodal region and can be 
seen before the onset of clinical symptoms in the absence of inflammatory infiltration 
and demyelination (Howell et al., 2010) and are likely to involve excitotoxic insult to 
oligodendrocytes. In our model microglial activation can also be seen in the optic 
nerve during the induction phase and might therefore contribute to axonal changes 
that precede inflammation, demyelination and axonal loss. 
In the retina, microglial activation correlated with RGC degeneration, which started 
prior to the onset of optic neuritis. The fact that microglial activation is an early event 
in lesion formation and correlates with death of RGCs, underlines the importance of 
microglial activation and as a target for early intervention/neuroprotective therapies. 
The antibioticum minocycline, which inhibits microglial activation (Yrjänheikki et al., 
1998; Tikka et al., 2002), is currently examined as a possible anti-inflammatory and 
neuroprotective therapy in several diseases including MS, ALS and Parkinson´s 
disease as it shows beneficial effects in animal models of these diseases and also in 
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models of stroke and TBI (reviewed by Yong et al., 2004). Experiments in animals 
with optic neuritis and after optic nerve axotomy show that minocycline treatment is 
beneficial for RGC survival and several mechanisms are suggested, including 
reduced glutamate concentration as a result of decreased microglial activation and 
upregulation of glutamate transporters in astrocytes (Maier et al., 2007). Since both 
activation of microglia and astrocytes can be observed during the induction phase in 
the retina, minocycline could prove beneficial in reducing early death of RGCs. 
The mechanism by which microglia are activated in the absence of robust T-cell 
infiltration is unclear but it has been proposed that small numbers of perivascular T-
cells might mediate BBB disturbances and cause influx of pro-inflammatory cytokines 
and/or fibrin which may then activate microglia (Marik et al., 2007) and experiments 
in our model showed localised disturbance in the integrity of the blood-retinal-barrier 
during the induction phase (Fairless et al., under revision). 
As mentioned above a mechanism by which microglia could contribute to early 
neurodegeneration of retinal ganglion cells and axonal damage is glutamate toxicity. 
Activated microglia and macrophages can secrete glutamate (Piani et al., 1991; 
Takeuchi et al., 2005; Takeuchi et al., 2006, Barger et al., 2007). Inhibition of 
glutaminase and blocking of gap junctions with carbenoxolone (CBX) decreased 
extracellular concentration of glutamate in microglial cultures and also reduced death 
of co-cultured neurons (Yawata et al., 2008). Treatment with CBX attenuated 
symptoms in mice with EAE and promoted survival of neurons in culture with LPS-
stimulated activated microglia (Shijie et al., 2009). Since activation of microglia 
correlates well with onset of RGC degeneration, excitotoxicity caused by microglial 
glutamate release is a potential contributor to early RGC death. As mentioned before 
activation of microglia correlates with axoglial alterations in NAWM of patients and 
spinal cord in rats with EAE; the authors (Howell et al., 2010) suggest a role for 
microglia-derived glutamate since oligodendrocytes are vulnerable to excitotoxicity 
(Matute et al., 1997) and exposing spinal cords to glutamate causes paranodal 
myelin retraction (Fu et al., 2009). 
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5.3 Reactive astrocytes and Müller cells can have beneficial and 
detrimental effects on neuronal survival 
In the retina two types of macroglia can be found: Astrocytes and Müller cells. 
Astrocytes are restricted to the ganglion cell layer and nerve fiber layers, Müller cell 
bodies are located in the inner nuclear layer and project processes throughout the 
retina. These glial cells perform a variety of different, overlapping functions, among 
them providing growth factors, ion buffering and maintaining homeostasis of 
neurotransmitters, including glutamate by taking it up via sodium-dependent 
glutamate transporters. In the retina the Glutamate Aspartate Transporter (GLAST) is 
the principle transporter for maintaining low glutamate concentration (Rauen et al., 
1998; Harada et al., 1998) and is expressed both in Müller cells and astrocytes (Otori 
et al., 1994). One of the most common markers for altered glial reactivity is GFAP 
(Norton et al., 1992; Lam et al., 1995; Chen and Weber, 2002) and increased GFAP 
expression can be found in retinal injuries such as ischemia and glaucoma (Osborne 
et al., 1991; Wang et al., 2000). In this study an increase in GFAP expression could 
be seen from d5 p.i. onwards, both in the retinal ganglion cell layer and also in the 
inner plexiform layer (Figure 4.14), suggesting increased reactivity in astrocytes and 
Müller cells.  
There are several mechanisms by which glial cells can contribute to both 
neurodegeneration and neuroprotection. Glial cells provide trophic support for 
neuronal cells, and upon injury, increased expression of neurotophic factors and 
growth factors can promote neuronal survival (reviewed by Bringman et al., 2009; 
Nair et al., 2008). Astrocytes and Müller cells can secrete pro-inflammatory cytokines 
including IL-6 and TNF-α (Dong and Benveniste, 2001; Yoshida et al., 2001), and 
chemokines, contributing to neuronal injury, but TNF-α has also been implied in 
rescue of RGCs after optic nerve axotomy (Diem et al., 2001). Chemokine 
expression of astrocytes has been shown to play a role in microglia/macrophage 
activation in secondary progressive MS (Tanuma et al., 2006). Reactive astrocytes 
show elevated levels of inducible nitric oxide synthase (iNOS) when exposed to 
elevated hydrostatic pressure (Neufeld and Liu, 2003). iNOS produces nitric oxide 
(NO) and which can damage both axons and neurons (Smith et al., 2001, Morgan et 
al., 1999). A beneficial role of reactive gliosis during the acute phase of EAE is 
supported by studies where astrocytosis was inhibited in mice with EAE and an 
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increased infiltration with macrophages and more severe disease course could be 
observed, suggesting a role for reactive astrocytosis in controlling leukocyte 
infiltration (Voskuhl et al., 2009; Toft-Hansen et al., 2011). As mentioned before, glial 
glutamate transporters are important for maintaining low extracellular glutamate 
concentration and malfunction of glutamate transporters can contribute to increased 
glutamate levels, causing exctitotoxic damage to neurons. Down-regulation of 
GLAST has been observed in spinal cord astrocytes in Lewis rats with EAE (Ohgoh 
et al., 2002) and downregulation of GLAST was observed in astrocytes co-cultured 
with autoreactive T-cells (Korn et al., 2005), suggesting reactive gliosis and 
subsequent impairment of glutamate uptake as a mechanism contributing to 
glutamate-mediated neuronal death.  
 
5.4 Increased concentration of biomarkers in the CSF and blood did not 
correlate with early degeneration of RGCs 
In MS patients, intensive efforts have been directed at the identification of biomarkers 
from body fluids, especially blood and CSF, in order to get a better understanding of 
MS pathogenesis and to predict the conversion to MS after a first clinical episode, 
disease course and future disability, selection of patients for individual treatment and 
for monitoring disease activity and treatment response (Tumani et al., 2009; 
Dujmovic, 2011).  
There are several categories of potential biomarkers, among them are markers 
indicating changes in the immune system (cytokines such as TNF-α, different 
interleukins and IFN-γ), markers connected to demyelination and humoral immune 
response (anti-MOG and anti-MBP antibodies) and markers for neuroaxonal damage 
(tau, Neurofilament L and H) (Tumani et al., 2009; Dujmovic, 2011; Bielekova and 
Martin, 2004).  
CSF levels of pro-inflammatory cytokines are usually elevated in MS patients and 
increased concentrations of IFN-γ and TNF-α have also been found in the CSF of 
mice with EAE (Willenborg et al, 1995). Microglia can be both recipients of and 
secrete pro-inflammatory cytokine such as IL-1β, IFN-γ and TNF-α (Hinkerohe et al., 
2005; Hanisch, 2002). Since it has been proposed that liberation of pro-inflammatory 
cytokines might contribute to early activation of microglia (Marik et al. 2007), the CSF 
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of rats both from the induction phase and after onset of clinical symptoms was 
examined for changes in the concentration of several cytokines. No changes could 
be seen in the concentration of Il-4, IL-5, IL-13, IL-1β, IFN-γ or TNF-α during the 
induction or clinical phase. It might be possible that the assay used was not sensitive 
enough to detect changes since increased expression of TNF-α mRNA parallels 
disease course during EAE (Issazadeh et al., 1995) and increased TNF-α 
concentration in the CSF of Lewis rats with EAE has been observed (Villarroya et al., 
1996), suggesting that increased concentrations of cytokines are likely to be 
observed at least after onset of clinical symptoms. There was a significant increase in 
the concentration of CXCL1 on d1 of EAE (Figure 4.15). CXCL1 is secreted by 
reactive astrocytes and activated microglia/macrophages and binds to the CXCR2 
receptor which is expressed on neutrophils and responsible for their chemotactic 
response (Bozic et al., 1995; Van Damme et al., 1997), thereby promoting 
inflammation. 
As mentioned before neurodegeneration has become a focus of research because 
clinical disability correlates with neurodegeneration and axonal pathology (De 
Stefano et al., 1998; Bjartmar and Trapp, 2003). A potential biomarker for axonal 
degeneration is the microtubule-associated protein tau. Tau protein concentration 
has been investigated in numerous studies in MS patients. Most studies show a 
significant increase in tau concentration in the CSF of patients but this finding is not 
unanimous (reviewed by Tumani et al., 2008). In our model, a significant increase in 
tau protein concentration could be seen on d1 and d8 of EAE, correlating with axonal 
loss observed with Bielschowsky silver impregnation (Figure 4.5 and Figure 4.6). 
Axonal changes during the induction phase might not have been extended enough to 
raise tau concentration to detectable levels which may provide further evidence that 
RGC degeneration is occurring before widescale axonal damage. 
Immunisation with MOG is known to elicit a humoral immune response in our model 
and a significant increase in the concentration of anti-MOG antibodies in the serum 
was observed from d10 p.i. onwards in my experiments (Figure 4.12), thus 
preceeding the onset of clinical symptoms. A significant increase in the number of 
activated microglia could be seen in MOG-immunised animals but not in sham-
immunised controls at the same time point (Figure 4.8 and Figure 4.13), emphasizing 
the MOG-specifity of microglial activation. However, a detectable level of anti-MOG 
antibodies was first observed 5 days after onset of microglial activation and RGC 
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degeneration, suggesting that microglial activation is not directly mediated by anti-
MOG antibodies. 
 
5.5 Optic neuritis can be developed independently from clinical 
symptoms 
 
Not all immunised animals developed clinical symptoms of EAE. Animals without 
symptoms were sacrificed on d30 p.i. and the ONs were examined for signs of optic 
neuritis. In 50% of the ONs, the ED1 positive cells had a microglia-like phenotype 
and no demyelination could be seen (Figure 4.10; D and A). The number of ED1 
positive cells was significantly higher than on d10 p.i. (Figure 4.10, L). A possible 
explanation might be the longer time period after immunisation in which more of the 
resident microglia can be activated and also more CD3 positive cells could be seen 
compared to healthy and sham-immunised animals, contributing to microglial 
activation.  
The remaining 50% of the ONs showed strong demyelination and reduced axonal 
density (Figure 4.10, E and F). Both demyelination and reduction in axonal density 
were significantly more severe in these animals than in animals sacrificed on d1 of 
EAE. Animals developed clinical symptoms on average by d17 p.i. and were then 
sacrificed, whereas animals without clinical symptoms were sacrificed on d30 p.i. 
Assuming that they developed optic neuritis around the same time the more 
extensive demyelination and axonal loss could be explained by the longer period of 
time after onset of optic neuritis. 
These results show that animals can develop optic neurits independently from spinal 
cord symptoms and that the incidence of optic neuritis is much higher than that of 
EAE. In patients with MS, optic neuritis is often one of the first symptoms therefore it 
is not surprising that animals with EAE also develop optic neuritis early. The 
possibility remains that animals with optic neuritis would have developed spinal cord 
symptoms later on. Reasons for the early development of optic neuritis without the 
occurrence of spinal cord symptoms could be for one the higher permeability of the 
BBB around the optic nerve when compared to the permeability of the BBB at the 
spinal cord which could lead to higher numbers of infiltrating inflammatory cells 
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around the ON. It has been shown that the BBB at the ON head is incomplete and 
thus more permeable than in other areas (Tso et al., 1975; Hu et al., 1998; Hofman 
et al., 2001). The higher expression of MOG in the ON compared to expression in the 
spinal cord (Betelli et al., 2003) could lead to more extensive immune response in the 
ON after infiltration with MOG specific T-cells. 
 
5.6 Calcium influx in the retina and optic nerve started during the 
induction phase and in the retina it correlated with onset of RGC 
degeneration  
In the retina a significant increase in contrast enhancement could be seen on d5 p.i, 
d10 p.i and d1 of EAE (Figure 4.20), suggesting an increase in calcium influx. The 
onset of manganese enhancement correlated well with microglial activation in the 
retina and onset of RGC degeneration. Experiments with the NMDA-receptor inhibitor 
MK801 showed that contrast enhancement is significantly reduced at d5 p.i when 
animals are pretreated with the inhibitor (Figure 4.21), suggesting a role for calcium 
influx via NMDA-receptors at this timepoint. Since treatment with MK801 reduces 
calcium influx and glutamate-induced cell death in cultured RGCs (Pang et al., 2007; 
Hartwick et al., 2008), NMDA receptor modulation might also be considered as a 
therapeutical target to decrease early death of RGCs. In the optic nerve a significant 
increase in manganese enhancement could be seen from d10 p.i. onwards (Figure 
4.18). It has been shown that exposing spinal cords to glutamate causes paranodal 
myelin retraction and a subsequent increase in axonal calcium influx can be 
observed at these exposed paranodes (Fu et al., 2009). Subtle myelin abnormalities 
starting prior to onset of optic neuritis might make these exposed structures more 
vulnerable to T-cell or antibody-mediated attacks (Howell et al., 2010) and axons 
showing alterations and increased calcium influx during the induction phase are 
therefore likely to be the first affected after onset of optic neuritis. 
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5.7 Increased calpain activity in the optic nerve and retina correlated 
with calcium influx and onset of RGC degeneration 
In the retina, the amount of calpain-mediated spectrin breakdown product is 
significantly increased on d5 and d7 p.i, suggesting increased calpain activity. Since 
onset of RGC degeneration correlates with increased amounts of spectrin breakdown 
product, increased calpain activity is likely to be involved in early death of RGCs. 
This is supported by in vitro data demonstrating that calpain activity is increased in 
cultured RGCs after serum starvation and calcium ionophore treatment and that 
calpain inhibitors promote cell survival in these experiments (Mc Kernan et al., 2007). 
Additionally, the calpain inhibitor SNJ-1945 ameliorated retinal degeneration in an 
animal model of glaucoma (Oka et al., 2006a). Proteolysis and hyperphosphorylation 
of tau have been proposed as neurotoxic (Azuma and Shearer, 2008) and calpain 
may play a role in both processes. Induction of hypoxia in rat retinas leads to the 
production of a calpain-specific spectrin breakdown product, proteolysis of pro-
caspase 3 and proteolysis of tau. The calpain inhibitor SJA6017 partially inhibited the 
production of these fragments (Tamada et al., 2005). In a rat model of glaucoma, 
elevated pressure leads to proteolysis of tau, spectrin and p35 in the retina (Oka et 
al., 2006, b). There is increasing evidence of cross-talk between the calpain and 
caspase system (Camins et al., 2006). As mentioned before calpain can cleave pro-
caspase 3 into an active form and caspase 3 can cleave the calpain inhibitor 
calpastatin. These findings make it very plausible that the increased calpain activity 
in this model plays a crucial role in the early degeneration of RGCs. The reduction in 
spectrin breakdown product later on might be due to further degradation of spectrin 
into products that are no longer recognized by the specific antibody. 
In the optic nerve calpain activation can bee seen from d10 p.i. onwards, correlating 
with increased manganese enhancement. As mentioned before, calpain can cleave 
several cytoskeletal proteins, among them β4-spectrin and ankyrin (Hall et al., 1987; 
Lövfenberg and Backmann, 1999). β4-spectrin binds ankyrin G to the plasma 
membrane and actin cytoskeleton (Berghs et al., 2000; Bennett and Baines, 2001) 
and in the nodes of Ranvier and the axonal initial segment (AIS), the localization of 
NaV-channels is highly correlated with that of β4-spectrin and ankyrin G (Kordeli et 
al., 1995; Bennett and Baines, 2001). In β4-spectrin and ankyrin null neurons, 
voltage-gated sodium channels are not clustered correctly (Komada and Soriano, 
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2002). Increased calcium concentration causes a concentration-dependent calpain-
mediated proteolysis of β4-spectrin and ankyrin G at the AIS and loss of ion channel 
clustering. Inhibition of calpain was sufficient to preserve the structure of the AIS 
(Schafer et al., 2009). The molecular organisation at the nodes of Ranvier is very 
similar with the same β4-spectrin and ankyrin G-based cytoskeleton (Susuki and 
Rasband, 2008), suggesting similar results. Increased calpain activation during the 
induction phase could therefore contribute to subtle axonal changes, including more 
diffuse localisation of sodium channels around the nodes of Ranvier. 
5.8 Reduced degeneration of RGCs and reduced severity of optic 
neuritis under calpeptin treatment suggests a role for increased 
calpain activity in these events 
Treatment with the calpain inhibitor calpeptin is known to reduce the capability of T-
cells to migrate into the CNS and to reduce inflammation, demyelination and axonal 
loss in the spinal cord (Guyton et al., 2010). In our model, treatment with calpeptin 
from the day of immunisation onwards reduced infiltration with T-cells and 
macrophages, demyelination and accumulation of APP in the optic nerve. There was 
also significant reduction of RGC death during the clinical phase, likely to be 
connected to reduced severity of optic neuritis, confirming results from experiments 
in Lews rats with EAE where calpeptin treatment reduced death of RGCs after onset 
of optic neuritis (Smith et al., 2011). As mentioned before in our model RGC 
degeneration starts in the induction phase of EAE, prior to onset of optic neuritis. The 
early death of RGCs is accompanied by increased microglial activation in the retina, 
calcium influx and increased amount of calpain-specific spectrin breakdown product, 
suggesting an increase in calpain activity. It has been shown that calpeptin treatment 
reduces death of cultured RGCs after calcium influx, suggesting that calpain activity 
is an important factor in RGC degeneration caused by elevated calcium 
concentration (Das et al., 2006). Treatment with calpeptin significantly reduced the 
degeneration of RGCs in the induction phase. These results suggest that increased 
calpain activity plays an important role in the early degeneration of RGCs which can 
be observed in our model and that calpeptin treatment could be considered as a 
potential neuroprotective therapy. 
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